{"filepath": "../L2M3_data/0_csd_related_papers/ACS_XML/cg8b00352.xml", "publisher": "acs", "elements": [{"idx": 1, "type": "text", "classification": ["else"], "content": "<p>In this study, we\naim to develop a robust crystallization process\nfor the ionic cocrystal between piracetam and CaCl<sub>2</sub>. We\ndiscuss the structural characteristics of the piracetam-CaCl<sub>2</sub> cocrystal and its thermal behavior; furthermore, we develop a robust\ncrystallization process by construction of appropriate phase diagrams.\nCaCl<sub>2</sub> and piracetam form an ionic dihydrate cocrystal with\nformula piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O, in which the Ca<sup>2+</sup> cation adopts an octahedral coordination\nwith the oxygens of four different molecules of piracetam and of two\nwater molecules. According to the TGA, DSC, and VT-XRPD, the cocrystal\nexhibits improved thermal stability compared to the parent drug compound.\nIn this article we show how one can develop a robust, water-based\ncocrystallization process for ionic cocrystals, a relatively underexplored\npart of the cocrystal landscape. We also discuss the common ion effect\non cocrystallization, and show how a common ion can strongly impact\non the solubility of the cocrystal, as well as its constituting components.\nIn addition, a common ion will also strongly impact the size of the\ncocrystal region in the ternary phase diagram.</p>", "clean_text": "In this study, we aim to develop a robust crystallization process for the ionic cocrystal between piracetam and CaCl2. We discuss the structural characteristics of the piracetam-CaCl2 cocrystal and its thermal behavior; furthermore, we develop a robust crystallization process by construction of appropriate phase diagrams. CaCl2 and piracetam form an ionic dihydrate cocrystal with formula piracetam2\u22c5CaCl2\u22c52H2O, in which the Ca2+ cation adopts an octahedral coordination with the oxygens of four different molecules of piracetam and of two water molecules. According to the TGA, DSC, and VT-XRPD, the cocrystal exhibits improved thermal stability compared to the parent drug compound. In this article we show how one can develop a robust, water-based cocrystallization process for ionic cocrystals, a relatively underexplored part of the cocrystal landscape. We also discuss the common ion effect on cocrystallization, and show how a common ion can strongly impact on the solubility of the cocrystal, as well as its constituting components. In addition, a common ion will also strongly impact the size of the cocrystal region in the ternary phase diagram.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 2, "type": "text", "classification": ["else"], "content": "<p>This work\nfocuses on the development of a cocrystallization\nprocess for an ionic cocrystal from water. Using ternary phase diagrams,\nwe developed a robust up-scalable process for the water-piracetam-CaCl<sub>2</sub> system. The ternary phase diagram shows the system to behave\ncongruently in water, allowing the development of a robust cocrystallization\nprocess by a stoichiometric amount of piracetam and CaCl<sub>2</sub>. Furthermore, we discuss the common ion effects for these systems.</p>", "clean_text": "This work focuses on the development of a cocrystallization process for an ionic cocrystal from water. Using ternary phase diagrams, we developed a robust up-scalable process for the water-piracetam-CaCl2 system. The ternary phase diagram shows the system to behave congruently in water, allowing the development of a robust cocrystallization process by a stoichiometric amount of piracetam and CaCl2. Furthermore, we discuss the common ion effects for these systems.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 3, "type": "text", "classification": ["else"], "content": "<title>Introduction</title><p>A cocrystal is a solid\nform including a stoichiometric ratio of\nat least two different components, which are both solid under ambient\nconditions. Pharmaceutical cocrystals\nare cocrystals for which one of the two components is an active pharmaceutical\ningredient (API). Cocrystallization is a potentially\nattractive method to improve physicochemical properties of APIs, such\nas solubility, (thermal) stability, hygroscopicity, dissolution rate,\nand bioavailability, especially for non-ionizable APIs. Recently the FDA revised its viewpoint\non cocrystals, now defining them as APIs in contrast to drug product\nintermediates (DPIs) in the 2013 guidance. Therefore, cocrystallization\nis regarded as a promising approach in the pharmaceutical industry.</p>", "clean_text": "Introduction\n\nA cocrystal is a solid form including a stoichiometric ratio of at least two different components, which are both solid under ambient conditions. Pharmaceutical cocrystals are cocrystals for which one of the two components is an active pharmaceutical ingredient (API). Cocrystallization is a potentially attractive method to improve physicochemical properties of APIs, such as solubility, (thermal) stability, hygroscopicity, dissolution rate, and bioavailability, especially for non-ionizable APIs. Recently the FDA revised its viewpoint on cocrystals, now defining them as APIs in contrast to drug product intermediates (DPIs) in the 2013 guidance. Therefore, cocrystallization is regarded as a promising approach in the pharmaceutical industry.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 4, "type": "text", "classification": ["else"], "content": "<p>Ionic cocrystals (ICCs) form a particular type of subset in the\ncocrystal family, as the cocrystal former (coformer) is a salt. They have gained increasing popularity over recent years, as they\ncombine characteristics of typical molecular crystals with those of\nionic salts, like an alkali or alkaline earth halide. ICCs can improve\nthe parent compound\u2019s stability because of interactions between\nthe organic moiety and the ions from the salt. For example, when an alkali or alkaline earth halide is used as\ncoformer, the electron-rich atoms in the API interact directly with\nthe metal cations, and the halide ions could interact with other molecules\n(like water) if the ligand has hydrogen bonding ability. Recently\nthis type of cocrystals has been used in the context of chiral resolution. Typically, ICCs are obtained by methodologies common to cocrystals,\nsuch as solvent evaporation, mechanochemistry, and melt cocrystallization.\nInorganic salts are usually GRAS compounds (Generally Regarded As\nSafe), and economic reagents, and therefore, ICCs carry strong potential\nin the field of cocrystallization.</p>", "clean_text": "Ionic cocrystals (ICCs) form a particular type of subset in the cocrystal family, as the cocrystal former (coformer) is a salt. They have gained increasing popularity over recent years, as they combine characteristics of typical molecular crystals with those of ionic salts, like an alkali or alkaline earth halide. ICCs can improve the parent compound's stability because of interactions between the organic moiety and the ions from the salt. For example, when an alkali or alkaline earth halide is used as coformer, the electron-rich atoms in the API interact directly with the metal cations, and the halide ions could interact with other molecules (like water) if the ligand has hydrogen bonding ability. Recently this type of cocrystals has been used in the context of chiral resolution. Typically, ICCs are obtained by methodologies common to cocrystals, such as solvent evaporation, mechanochemistry, and melt cocrystallization. Inorganic salts are usually GRAS compounds (Generally Regarded As Safe), and economic reagents, and therefore, ICCs carry strong potential in the field of cocrystallization.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 5, "type": "text", "classification": ["else"], "content": "<p>Even though the research\nconcerning ionic cocrystallization has\ngreatly increased over the last years, the upscaling of an ionic cocrystallization\nprocess is rarely explored. Solution crystallization is still considered\nthe process of industrial relevance for the synthesis of end products\nwhich meet the regulatory requirements concerning purity and quality. In the context of cocrystallization, purity\nalso implies solid form purity. Form mixtures of cocrystal with one\nof its pure constituents can occur during cocrystallization from solution,\nand a robust cocrystallization process is required to handle these\nissues. The goal of this paper is to develop a robust cocrystallization\nprocess of an ionic cocrystal from solution. This is done by first\nanalyzing the different possible cocrystal forms as well as to identify\nthe most stable cocrystal form under ambient conditions, by studying\nthe thermal behavior of the cocrystal. After this, appropriate phase\ndiagrams are introduced and constructed which is a requirement for\nrobust process design. Finally, a robust upscaled cooling crystallization\nwill be presented on Piracetam-CaCl<sub>2</sub> dihydrate chosen as\na model ionic cocrystal.</p>", "clean_text": "Even though the research concerning ionic cocrystallization has greatly increased over the last years, the upscaling of an ionic cocrystallization process is rarely explored. Solution crystallization is still considered the process of industrial relevance for the synthesis of end products which meet the regulatory requirements concerning purity and quality. In the context of cocrystallization, purity also implies solid form purity. Form mixtures of cocrystal with one of its pure constituents can occur during cocrystallization from solution, and a robust cocrystallization process is required to handle these issues. The goal of this paper is to develop a robust cocrystallization process of an ionic cocrystal from solution. This is done by first analyzing the different possible cocrystal forms as well as to identify the most stable cocrystal form under ambient conditions, by studying the thermal behavior of the cocrystal. After this, appropriate phase diagrams are introduced and constructed which is a requirement for robust process design. Finally, a robust upscaled cooling crystallization will be presented on Piracetam-CaCl2 dihydrate chosen as a model ionic cocrystal.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 6, "type": "text", "classification": ["else"], "content": "<title>Materials and Methods</title><title>Materials</title><p>Piracetam was purchased at Xiamen Top Health\nBiochem Tech. Co. Ltd. Calcium chloride anhydrous powder was purchased\nfrom ACROS. All the solvents were reagent grade.</p><title>Solid State\nSynthesis</title><p>The ICC can be obtained mechanochemically\nthrough liquid-assisted grinding of equimolar mixtures of piracetam\nand CaCl<sub>2</sub>, with the addition of 10 \u03bcL of methanol.\nThe sample was ground in a RETSCH Mixer Mill MM 400 for 90 min with\na beating frequency of 30 Hz. The powders were characterized by powder\nX-ray diffraction (XRPD) and the resulting diffraction pattern compared\nwith the diffraction pattern of the pure phases.</p>", "clean_text": "Materials and Methods\n\nMaterials\n\nPiracetam was purchased at Xiamen Top Health Biochem Tech. Co. Ltd. Calcium chloride anhydrous powder was purchased from ACROS. All the solvents were reagent grade.\n\nSolid State Synthesis\n\nThe ICC can be obtained mechanochemically through liquid-assisted grinding of equimolar mixtures of piracetam and CaCl2, with the addition of 10 \u03bcL of methanol. The sample was ground in a RETSCH Mixer Mill MM 400 for 90 min with a beating frequency of 30 Hz. The powders were characterized by powder X-ray diffraction (XRPD) and the resulting diffraction pattern compared with the diffraction pattern of the pure phases.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 7, "type": "text", "classification": ["synthesis condition"], "content": "<title>Single Crystal\nSynthesis</title><p>An equimolar mixture of Piracetam\n(14.2 mg, 1.00 mmol) and CaCl<sub>2</sub> (11.1 mg, 1.00 mmol) was\ndissolved in ethanol (2 mL) and left to evaporate over 3 days to get\nsuitable crystals for single crystal diffraction. Single crystals\nof piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O were obtained, as confirmed by single crystal X-ray diffraction\nand powder diffraction experiments.</p>", "clean_text": "Single Crystal Synthesis\n\nAn equimolar mixture of Piracetam (14.2 mg, 1.00 mmol) and CaCl2 (11.1 mg, 1.00 mmol) was dissolved in ethanol (2 mL) and left to evaporate over 3 days to get suitable crystals for single crystal diffraction. Single crystals of piracetam2\u22c5CaCl2\u22c52H2O were obtained, as confirmed by single crystal X-ray diffraction and powder diffraction experiments.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['synthesis condition']"}}, {"idx": 8, "type": "text", "classification": ["else"], "content": "<title>Ternary Phase Diagram</title><p>Ternary phase diagrams were determined\nby creating suspensions of varying relative amounts of piracetam and\nCaCl<sub>2</sub> using a fixed amount of water as solvent. The piracetam/CaCl<sub>2</sub> molar ratio was varied from 0 to 1, which yields the experimental\nstarting points shown by the blue crosses in . Experiments were carried out in several\n2 mL sealed vials. The suspensions were seeded with cocrystal Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O and stirred at\nconstant temperature over 48 h to make sure that the system reached\nthermodynamic equilibrium. Then samples were filtered over sintered\nglass, followed by XRPD analysis of the solid phases. To determine\nthe solubility lines (red curves in ), samples with identical proportions as\nthose mentioned above were prepared. After 48 h, the samples were\ndiluted under continuous stirring, by addition of 30 \u03bcL water\nevery 30 min. Upon total dissolution, observed visually, a given point\non the solubility line is obtained. Alternatively, one could quantitatively\nanalyze the supernatant solution. However, as this would imply quantifying\nan organic compound as well as an inorganic salt, the former approach\nis more practical in this specific case. When performing the dilution\nwith sufficiently small solvent addition steps, and sufficiently low\nwaiting times, accuracy of this method is comparable to other techniques.\nTPDs were drawn using ProSim Ternary Diagram software.</p>", "clean_text": "Ternary Phase Diagram\n\nTernary phase diagrams were determined by creating suspensions of varying relative amounts of piracetam and CaCl2 using a fixed amount of water as solvent. The piracetam/CaCl2 molar ratio was varied from 0 to 1, which yields the experimental starting points shown by the blue crosses in . Experiments were carried out in several 2 mL sealed vials. The suspensions were seeded with cocrystal Piracetam2\u22c5CaCl2\u22c52H2O and stirred at constant temperature over 48 h to make sure that the system reached thermodynamic equilibrium. Then samples were filtered over sintered glass, followed by XRPD analysis of the solid phases. To determine the solubility lines (red curves in ), samples with identical proportions as those mentioned above were prepared. After 48 h, the samples were diluted under continuous stirring, by addition of 30 \u03bcL water every 30 min. Upon total dissolution, observed visually, a given point on the solubility line is obtained. Alternatively, one could quantitatively analyze the supernatant solution. However, as this would imply quantifying an organic compound as well as an inorganic salt, the former approach is more practical in this specific case. When performing the dilution with sufficiently small solvent addition steps, and sufficiently low waiting times, accuracy of this method is comparable to other techniques. TPDs were drawn using ProSim Ternary Diagram software.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 9, "type": "figure", "classification": null, "content": "<fig fig-type=\"scheme\" id=\"sch1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Typical\nProcess for Determining the Ternary Phase Diagram of an Ionic\nCocrystal</title>\n</caption>\n<graphic id=\"gr1\" position=\"float\" xlink:href=\"cg-2018-00352c_0006.tif\"></graphic>\n</fig>", "clean_text": " 1  Typical Process for Determining the Ternary Phase Diagram of an Ionic Cocrystal   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 10, "type": "text", "classification": ["else"], "content": "<title>Powder X-ray Diffraction\n(XRPD)</title><p>X-ray powder diffraction\nmeasurements were performed on a Siemens D5000 diffractometer equipped\nwith a Cu X-ray source operating at 40 kV and 40 mA and the secondary\nmonochromator allowing to select the K\u03b1 radiation of Cu (\u03bb\n= 1.5418 \u00c5). A scanning range of 2\u03b8 values from 5\u00b0\nto 50\u00b0 at a scan rate of 0.6\u00b0 min<sup>\u20131</sup> was\napplied. The results were analyzed by the FullProf Suite software\npackage.</p>", "clean_text": "Powder X-ray Diffraction (XRPD)\n\nX-ray powder diffraction measurements were performed on a Siemens D5000 diffractometer equipped with a Cu X-ray source operating at 40 kV and 40 mA and the secondary monochromator allowing to select the K\u03b1 radiation of Cu (\u03bb = 1.5418 \u00c5). A scanning range of 2\u03b8 values from 5\u00b0 to 50\u00b0 at a scan rate of 0.6\u00b0 min-1 was applied. The results were analyzed by the FullProf Suite software package.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 11, "type": "text", "classification": ["else"], "content": "<title>Single Crystal X-ray Diffraction</title><p>Single crystal X-ray\ndiffraction was performed on a MAR345 image plate using monochromated\nMo K\u03b1 radiation (\u03bb = 0.71073 \u00c5) (Xenocs Fox3D mirror)\nproduced by a Rigaku UltraX 18S rotating anode. The structures were\nsolved by SHELXT and refined on |<italic>F</italic>\n<sup>2</sup>| using\nSHELXL-2014/7. Non-hydrogen atoms were anisotropically refined and\nthe hydrogen atoms in riding mode with isotropic temperature factors\nfixed at 1.2 times <italic>U</italic>(eq) of the parent atoms.</p>", "clean_text": "Single Crystal X-ray Diffraction\n\nSingle crystal X-ray diffraction was performed on a MAR345 image plate using monochromated Mo K\u03b1 radiation (\u03bb = 0.71073 \u00c5) (Xenocs Fox3D mirror) produced by a Rigaku UltraX 18S rotating anode. The structures were solved by SHELXT and refined on |F 2| using SHELXL-2014/7. Non-hydrogen atoms were anisotropically refined and the hydrogen atoms in riding mode with isotropic temperature factors fixed at 1.2 times U(eq) of the parent atoms.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 12, "type": "text", "classification": ["else"], "content": "<title>Thermogravimetric\nAnalysis (TGA)</title><p>TGA measurements were\nperformed on a Mettler Toledo TGA/SDTA851<sup>e</sup> using an alumina\ncrucible. The heating profile applied starts at 25\u202f\u00b0C\nand goes up to 500 \u00b0C with a rate of 2 \u00b0C/min under continuous\nnitrogen flow of 50.0 mL/min.</p>", "clean_text": "Thermogravimetric Analysis (TGA)\n\nTGA measurements were performed on a Mettler Toledo TGA/SDTA851e using an alumina crucible. The heating profile applied starts at 25\u00b0C and goes up to 500 \u00b0C with a rate of 2 \u00b0C/min under continuous nitrogen flow of 50.0 mL/min.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 13, "type": "text", "classification": ["else"], "content": "<title>Differential Scanning Calorimetry\n(DSC)</title><p>DSC measurements\nwere performed on a Mettler Toledo DSC 821<sup>e</sup> using 40 \u03bcL\naluminum crucibles with a pierced cap. The temperature profile applied\nstarts at 25 \u00b0C and increases up to 350 \u00b0C with a rate of\n2 \u00b0C/min.</p>", "clean_text": "Differential Scanning Calorimetry (DSC)\n\nDSC measurements were performed on a Mettler Toledo DSC 821e using 40 \u03bcL aluminum crucibles with a pierced cap. The temperature profile applied starts at 25 \u00b0C and increases up to 350 \u00b0C with a rate of 2 \u00b0C/min.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 14, "type": "text", "classification": ["else"], "content": "<title>Results and Discussion</title><title>Model System</title><p>As\na model compound, we chose Piracetam,\n2-oxo-1-pyrrolidine acetamide (), a nootropic agent marketed for the treatment of\nseveral neurodegenerative disorders such as Alzheimer\u2019s disease.\nFabbiani  et al. have discovered five polymorphic forms and two hydrate\nforms of piracetam. A search of the Cambridge Structural Database\nreports 9 cocrystals of piracetam with organic coformers: gentisic, citric and <sc>l</sc>-tartaric acids, mandelic, <italic>p</italic>-hydroxybenzoic and 4-hydroxybenzoic acids, gallic\nacid, as well as 2,6-diaminopyridine and myricetin. Piracetam\nis also prone to cocrystal formation with different inorganic salts,\nsuch as MnCl<sub>2</sub>, NiCl<sub>2</sub>, SrCl<sub>2</sub>, LiCl, and LiBr. In\nthis paper, we used the piracetam-CaCl<sub>2</sub> system as a model\nto develop a robust solution cocrystallization process for ionic cocrystals.</p>", "clean_text": "Results and Discussion\n\nModel System\n\nAs a model compound, we chose Piracetam, 2-oxo-1-pyrrolidine acetamide (), a nootropic agent marketed for the treatment of several neurodegenerative disorders such as Alzheimer's disease. Fabbiani  et al. have discovered five polymorphic forms and two hydrate forms of piracetam. A search of the Cambridge Structural Database reports 9 cocrystals of piracetam with organic coformers: gentisic, citric and l-tartaric acids, mandelic, p-hydroxybenzoic and 4-hydroxybenzoic acids, gallic acid, as well as 2,6-diaminopyridine and myricetin. Piracetam is also prone to cocrystal formation with different inorganic salts, such as MnCl2, NiCl2, SrCl2, LiCl, and LiBr. In this paper, we used the piracetam-CaCl2 system as a model to develop a robust solution cocrystallization process for ionic cocrystals.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 15, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig1\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Molecular\nstructure of piracetam.</p>\n</caption>\n<graphic id=\"gr2\" position=\"float\" xlink:href=\"cg-2018-00352c_0001.tif\"></graphic>\n</fig>", "clean_text": " 1  Molecular structure of piracetam.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 16, "type": "text", "classification": ["else"], "content": "<p>First, we studied the solid state of the model system and\ncompared\nit to the literature reference. By liquid-assisted\ngrinding (LAG) of an equimolar mixture of piracetam and CaCl<sub>2</sub> with 10 \u03bcL of methanol, one obtains a novel crystalline phase\n(), different\nfrom any of the known forms of the parent compounds. The resulting\npattern furthermore overlaps with that described for the Ca-Piracetam\ncocrystal system ().</p>", "clean_text": "First, we studied the solid state of the model system and compared it to the literature reference. By liquid-assisted grinding (LAG) of an equimolar mixture of piracetam and CaCl2 with 10 \u03bcL of methanol, one obtains a novel crystalline phase (), different from any of the known forms of the parent compounds. The resulting pattern furthermore overlaps with that described for the Ca-Piracetam cocrystal system ().", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 17, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig2\" position=\"float\">\n<label>2</label>\n<caption>\n<p>XRPD overlay of LAG of piracetam with CaCl<sub>2</sub> using 10\n\u03bcL of methanol (red) with the simulated XRPD of the cocrystal\n(blue).</p>\n</caption>\n<graphic id=\"gr3\" position=\"float\" xlink:href=\"cg-2018-00352c_0002.tif\"></graphic>\n</fig>", "clean_text": " 2  XRPD overlay of LAG of piracetam with CaCl2 using 10 \u03bcL of methanol (red) with the simulated XRPD of the cocrystal (blue).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 18, "type": "text", "classification": ["else"], "content": "<title>Structural Analysis</title><p>The first report on the structure\nof the Ca-Piracetam cocrystal comes from Braga  et al., solving the structure from powder X-ray diffraction.\nIn this paper, we are first to obtain this structure from single crystal\nanalysis. Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O crystallizes in a monoclinic space group <italic>P</italic>2<sub>1</sub>/<italic>n</italic> with two molecules of piracetam,\none molecule of CaCl<sub>2</sub>, and two H<sub>2</sub>O molecules\nin the unit cell (Z = 2) (). The Ca<sup>2+</sup> cation is found on an inversion\ncenter coordinated by six ligands. It forms an octahedral coordination\nwith the oxygens of four different molecules of piracetam occupying\nthe equatorial positions; the axial positions are taken up by water\nmolecules. Each piracetam interacts with two Ca<sup>2+</sup> cations\ngiving rise to 2D sheets of interconnected Ca<sup>2+</sup> octahedra.\nThe sheets expose the coordinated water molecules and NH<sub>2</sub> groups (amide) on either side, efficiently hydrogen bonding the\nCl<sup>\u2013</sup> anions that are wedged between the coordination\nsheets. Crystallographic parameters and refinement details are listed\nin .</p>", "clean_text": "Structural Analysis\n\nThe first report on the structure of the Ca-Piracetam cocrystal comes from Braga  et al., solving the structure from powder X-ray diffraction. In this paper, we are first to obtain this structure from single crystal analysis. Piracetam2\u22c5CaCl2\u22c52H2O crystallizes in a monoclinic space group P21/n with two molecules of piracetam, one molecule of CaCl2, and two H2O molecules in the unit cell (Z = 2) (). The Ca2+ cation is found on an inversion center coordinated by six ligands. It forms an octahedral coordination with the oxygens of four different molecules of piracetam occupying the equatorial positions; the axial positions are taken up by water molecules. Each piracetam interacts with two Ca2+ cations giving rise to 2D sheets of interconnected Ca2+ octahedra. The sheets expose the coordinated water molecules and NH2 groups (amide) on either side, efficiently hydrogen bonding the Cl- anions that are wedged between the coordination sheets. Crystallographic parameters and refinement details are listed in .", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 19, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig3\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Left: Coordination\naround the Ca<sup>2+</sup> cation in crystalline\npiracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.\nRight: A 2D-layer of Ca<sup>2+</sup> ions and coordinated water and\npiracetam molecules extending in the crystalline structure.</p>\n</caption>\n<graphic id=\"gr4\" position=\"float\" xlink:href=\"cg-2018-00352c_0003.tif\"></graphic>\n</fig>", "clean_text": " 3  Left: Coordination around the Ca2+ cation in crystalline piracetam2\u22c5CaCl2\u22c52H2O. Right: A 2D-layer of Ca2+ ions and coordinated water and piracetam molecules extending in the crystalline structure.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 20, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Crystallographic\nData of Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"2\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\">cocrystal piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>empirical formula</oasis:entry>\n<oasis:entry>C<sub>12</sub>H<sub>24</sub>CaCl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>M</oasis:entry>\n<oasis:entry>431.33</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>T</italic> [K]</oasis:entry>\n<oasis:entry>296(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>crystal system</oasis:entry>\n<oasis:entry>monoclinic</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>space group</oasis:entry>\n<oasis:entry>\n<italic>P</italic>2<sub>1</sub>/<italic>n</italic>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>a</italic> [\u00c5]</oasis:entry>\n<oasis:entry>8.9057(4)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>b</italic> [\u00c5]</oasis:entry>\n<oasis:entry>9.6203(4)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>c</italic> [\u00c5]</oasis:entry>\n<oasis:entry>11.9399(5)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b2 [\u00b0]</oasis:entry>\n<oasis:entry>108.077(4)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>V [\u00c5<sup>3</sup>]</oasis:entry>\n<oasis:entry>972.47(7)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>Z</italic>\n</oasis:entry>\n<oasis:entry>2</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03c1<sub>calcd</sub> [Mg m<sup>\u20133</sup>]</oasis:entry>\n<oasis:entry>1.473</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>F</italic> (000)</oasis:entry>\n<oasis:entry>452</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03bc [mm<sup>\u20131</sup>]</oasis:entry>\n<oasis:entry>0.632</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>crystal size [mm]</oasis:entry>\n<oasis:entry>0.48 \u00d7 0.40\n\u00d7 0.15</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b8 range (deg)</oasis:entry>\n<oasis:entry>3.205 to 26.012\u00b0</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>reflection collected/unique</oasis:entry>\n<oasis:entry>6845/1861</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>R</italic>\n<sub>int</sub>\n</oasis:entry>\n<oasis:entry>0.0377</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>GoF</oasis:entry>\n<oasis:entry>1.006</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>Threshold expression</oasis:entry>\n<oasis:entry>&gt;2\u03c3(I)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>R1 (obsd)</oasis:entry>\n<oasis:entry>0.0344</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>wR2\n(all)</oasis:entry>\n<oasis:entry>0.0805</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 21, "type": "text", "classification": ["property"], "content": "<title>Thermal Stability</title><p>TGA analysis (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S1</ext-link>) shows a 7.6% weight loss between 140 and 160 \u00b0C,\ncorresponding to the loss of 2 equiv of water (theoretical wt% = 8.36).\nTGA analysis indicates a single step water loss. DSC analysis (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S2</ext-link>) confirms the water loss at 140 \u00b0C\nas seen by the large endothermic signal. Variable-temperature XRPD\n(<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S3</ext-link>) was used to highlight the one-step\ndehydration to an anhydrate solid phase at 140 \u00b0C, leading to\na phase which remains unchanged up to 220 \u00b0C. From 240 \u00b0C\nonward, degradation occurs. As piracetam melts at 127 \u00b0C, the ICC allows improvement of the thermal stability\nof piracetam in the solid state.</p>", "clean_text": "Thermal Stability\n\nTGA analysis (Figure S1) shows a 7.6% weight loss between 140 and 160 \u00b0C, corresponding to the loss of 2 equiv of water (theoretical wt% = 8.36). TGA analysis indicates a single step water loss. DSC analysis (Figure S2) confirms the water loss at 140 \u00b0C as seen by the large endothermic signal. Variable-temperature XRPD (Figure S3) was used to highlight the one-step dehydration to an anhydrate solid phase at 140 \u00b0C, leading to a phase which remains unchanged up to 220 \u00b0C. From 240 \u00b0C onward, degradation occurs. As piracetam melts at 127 \u00b0C, the ICC allows improvement of the thermal stability of piracetam in the solid state.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['property']"}}, {"idx": 22, "type": "text", "classification": ["else"], "content": "<title>Ionic Cocrystallization\nProcess Development</title><p>Phase diagrams\nare crucial tools for the development of a robust crystallization\nprocess. Ternary phase diagrams (TPD) describe the thermodynamically\nstable equilibrium for different overall compositions (solvent, coformer,\nAPI) at a specific temperature and for a given pressure. Therefore, TPDs can serve as a guide to decide the end point of\na robust solution cocrystallization process as it is a guide to the\nconditions where the desired phase is also the thermodynamically stable\none. In our case, we developed the TPD for the\nwater-piracetam-CaCl<sub>2</sub> system, with the experimental data\nshown in  and  at 298.15 K.  gives the overall initial composition of the experimental\npoints selected, and the nature of the solid state obtained at equilibrium.  shows the amount\nof water that needs to be added to each of these initial compositions\nfor total dissolution to occur, and hence yields a solubility point.\nAll the experiments in this paper are performed under atmospheric\npressure.  represents\nthe graphical TPD generated from this data.</p>", "clean_text": "Ionic Cocrystallization Process Development\n\nPhase diagrams are crucial tools for the development of a robust crystallization process. Ternary phase diagrams (TPD) describe the thermodynamically stable equilibrium for different overall compositions (solvent, coformer, API) at a specific temperature and for a given pressure. Therefore, TPDs can serve as a guide to decide the end point of a robust solution cocrystallization process as it is a guide to the conditions where the desired phase is also the thermodynamically stable one. In our case, we developed the TPD for the water-piracetam-CaCl2 system, with the experimental data shown in  and  at 298.15 K.  gives the overall initial composition of the experimental points selected, and the nature of the solid state obtained at equilibrium.  shows the amount of water that needs to be added to each of these initial compositions for total dissolution to occur, and hence yields a solubility point. All the experiments in this paper are performed under atmospheric pressure.  represents the graphical TPD generated from this data.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 23, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl2\" position=\"float\">\n<label>2</label>\n<caption>\n<title>Initial\nExperimental Data for System\nof Water-Piracetam-CaCl<sub>2</sub> at 298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"8\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col8\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col4\" namest=\"col2\" rowsep=\"1\">initial\ncomponents</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col7\" namest=\"col5\" rowsep=\"1\">initial\ncomponents (mol\u00a0%)</oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O</oasis:entry>\n<oasis:entry align=\"center\">solid phase at equilibrium<xref ref-type=\"table-fn\" rid=\"t2fn1\"></xref>\n</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.202</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.798</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.185</oasis:entry>\n<oasis:entry>0.021</oasis:entry>\n<oasis:entry>0.794</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.168</oasis:entry>\n<oasis:entry>0.042</oasis:entry>\n<oasis:entry>0.790</oasis:entry>\n<oasis:entry>Pi\u00a0+\u00a0CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.150</oasis:entry>\n<oasis:entry>0.064</oasis:entry>\n<oasis:entry>0.786</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.131</oasis:entry>\n<oasis:entry>0.087</oasis:entry>\n<oasis:entry>0.782</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.062</oasis:entry>\n<oasis:entry>0.062</oasis:entry>\n<oasis:entry>0.875</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.051</oasis:entry>\n<oasis:entry>0.076</oasis:entry>\n<oasis:entry>0.873</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.039</oasis:entry>\n<oasis:entry>0.091</oasis:entry>\n<oasis:entry>0.870</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.027</oasis:entry>\n<oasis:entry>0.107</oasis:entry>\n<oasis:entry>0.867</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.014</oasis:entry>\n<oasis:entry>0.123</oasis:entry>\n<oasis:entry>0.864</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.245</oasis:entry>\n<oasis:entry>0.755</oasis:entry>\n<oasis:entry>CaCl<sub>2</sub>\n</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t2fn1\">\n<label>a</label>\n<p>Pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 24, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl3\" position=\"float\">\n<label>3</label>\n<caption>\n<title>Experimental Data for the Dissolution\nPoints at 298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"9\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col8\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col9\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col6\" namest=\"col4\" rowsep=\"1\">composition\nat dissolution point</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col9\" namest=\"col7\" rowsep=\"1\">composition\nat dissolution point (mol\u00a0%)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">amount of H<sub>2</sub>O added (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">total amount of H<sub>2</sub>O (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O\n(\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>48</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>0.115</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.885</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>39</oasis:entry>\n<oasis:entry>89</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>89</oasis:entry>\n<oasis:entry>0.114</oasis:entry>\n<oasis:entry>0.013</oasis:entry>\n<oasis:entry>0.873</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>34</oasis:entry>\n<oasis:entry>84</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>84</oasis:entry>\n<oasis:entry>0.109</oasis:entry>\n<oasis:entry>0.027</oasis:entry>\n<oasis:entry>0.864</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>56</oasis:entry>\n<oasis:entry>106</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>106</oasis:entry>\n<oasis:entry>0.079</oasis:entry>\n<oasis:entry>0.034</oasis:entry>\n<oasis:entry>0.886</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>83</oasis:entry>\n<oasis:entry>133</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>133</oasis:entry>\n<oasis:entry>0.057</oasis:entry>\n<oasis:entry>0.038</oasis:entry>\n<oasis:entry>0.905</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>58</oasis:entry>\n<oasis:entry>158</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>158</oasis:entry>\n<oasis:entry>0.041</oasis:entry>\n<oasis:entry>0.041</oasis:entry>\n<oasis:entry>0.917</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>75</oasis:entry>\n<oasis:entry>175</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>175</oasis:entry>\n<oasis:entry>0.031</oasis:entry>\n<oasis:entry>0.046</oasis:entry>\n<oasis:entry>0.923</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>0.021</oasis:entry>\n<oasis:entry>0.049</oasis:entry>\n<oasis:entry>0.930</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>0.014</oasis:entry>\n<oasis:entry>0.058</oasis:entry>\n<oasis:entry>0.928</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>85</oasis:entry>\n<oasis:entry>185</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>185</oasis:entry>\n<oasis:entry>0.008</oasis:entry>\n<oasis:entry>0.071</oasis:entry>\n<oasis:entry>0.921</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>49</oasis:entry>\n<oasis:entry>99</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>99</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.141</oasis:entry>\n<oasis:entry>0.859</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 25, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig4\" position=\"float\">\n<label>4</label>\n<caption>\n<p>TPD of water-piracetam-CaCl<sub>2</sub> at 298.15 K (mol %). The\ngreen zone highlights the zone where the cocrystal is the only stable\nphase in suspension. a: the full image of ternary phase diagram. b:\nenlargement of the upper part.</p>\n</caption>\n<graphic id=\"gr5\" position=\"float\" xlink:href=\"cg-2018-00352c_0004.tif\"></graphic>\n</fig>", "clean_text": " 4  TPD of water-piracetam-CaCl2 at 298.15 K (mol %). The green zone highlights the zone where the cocrystal is the only stable phase in suspension. a: the full image of ternary phase diagram. b: enlargement of the upper part.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 26, "type": "text", "classification": ["else"], "content": "<p>As illustrated in , the zone where the cocrystal is the only stable phase\nin\nsuspension is rather large. Furthermore, the diagram shows the system\nto behave congruently in water, which means that starting from a stoichiometric\nratio of piracetam vs CaCl<sub>2</sub> (2:1), one can access the zone\nwhere the cocrystal is the only stable phase in suspension by mere\nsolvent evaporation. Hence a stoichiometric amount of piracetam and\nCaCl<sub>2</sub> can be used in the development of a robust cocrystallization\nprocess.\n<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figures S4 and S5</ext-link> show the temperature to have little impact on the\noverall interpretation of the ternary system.</p>", "clean_text": "As illustrated in , the zone where the cocrystal is the only stable phase in suspension is rather large. Furthermore, the diagram shows the system to behave congruently in water, which means that starting from a stoichiometric ratio of piracetam vs CaCl2 (2:1), one can access the zone where the cocrystal is the only stable phase in suspension by mere solvent evaporation. Hence a stoichiometric amount of piracetam and CaCl2 can be used in the development of a robust cocrystallization process. Figures S4 and S5 show the temperature to have little impact on the overall interpretation of the ternary system.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 27, "type": "text", "classification": ["synthesis condition"], "content": "<p>Based on the TPD,\na solution cocrystallization process was suggested\nstarting with a stoichiometric amount of starting compounds. 15 g\nof piracetam and 5.86 g of CaCl<sub>2</sub> (0.5 equiv) were added\nto 18 mL of water. This corresponds to the large red dot shown in . By heating to 75\n\u00b0C all solid forms were dissolved, and under continuous stirring\nthe solution was then brought back to 25 \u00b0C, by removing the\nsolution from its 75 \u00b0C environment and placing it in a surrounding\nof 25 \u00b0C. Crystallization occurred spontaneously during cooling.\nHowever, to ensure that the thermodynamically stable cocrystal phase\nwas obtained, cocrystal seeding material was added, and the suspension\nleft to stir for 3 h. The suspension was then filtered, and the powder\nleft to dry. 5.80 g of dried cocrystal material was recovered, and\nshown to correspond to the dihydrate cocrystal phase (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S7</ext-link>) by XRPD of the bulk material. This\ncorresponds to a 25% yield, in alignment with the maximum theoretical\nyield of 29%, based on the TPD data. As mentioned above, the yield\ncan be increased optimizing the process conditions (amount of water,\nchanging the temperature, recycling the filtrate which contains a\nstoichiometric ration of CaCl<sub>2</sub> and piracetam), but this\ngoes beyond the scope of the current contribution.</p>", "clean_text": "Based on the TPD, a solution cocrystallization process was suggested starting with a stoichiometric amount of starting compounds. 15 g of piracetam and 5.86 g of CaCl2 (0.5 equiv) were added to 18 mL of water. This corresponds to the large red dot shown in . By heating to 75 \u00b0C all solid forms were dissolved, and under continuous stirring the solution was then brought back to 25 \u00b0C, by removing the solution from its 75 \u00b0C environment and placing it in a surrounding of 25 \u00b0C. Crystallization occurred spontaneously during cooling. However, to ensure that the thermodynamically stable cocrystal phase was obtained, cocrystal seeding material was added, and the suspension left to stir for 3 h. The suspension was then filtered, and the powder left to dry. 5.80 g of dried cocrystal material was recovered, and shown to correspond to the dihydrate cocrystal phase (Figure S7) by XRPD of the bulk material. This corresponds to a 25% yield, in alignment with the maximum theoretical yield of 29%, based on the TPD data. As mentioned above, the yield can be increased optimizing the process conditions (amount of water, changing the temperature, recycling the filtrate which contains a stoichiometric ration of CaCl2 and piracetam), but this goes beyond the scope of the current contribution.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['synthesis condition']"}}, {"idx": 28, "type": "text", "classification": "error", "content": "<title>Ionic Cocrystallization\nand the Common Ion Effect</title><p>Contrary\nto cocrystallization between two organic components, using an inorganic\nsalt as a coformer introduces a supplementary parameter that can be\nused to fine-tune process conditions and that, as a consequence, needs\nto be taken into account. Working with a polar solvent, the inorganic\nsalt dissociates in solution into its composing ions. By doing so,\na common ion effect due to ions initially present in the solvent could\noccur. Using the most simplistic model for cocrystal solubility, the\ncocrystal solubility product can be described as <italic>K</italic>\n<sub>sp</sub> = <italic>a</italic>\n<sub>pi</sub>\n<sup>2</sup>\u00b7<italic>a</italic>\n<sub>CaCl<sub>2</sub>\n</sub>\u00b7<italic>a</italic>\n<sub>H<sub>2</sub>0</sub>\n<sup>2</sup> \u2248 <italic>a</italic>\n<sub>pi</sub>\n<sup>2</sup>\u00b7<italic>a</italic>\n<sub>Ca<sup>2+</sup>\n</sub>\u00b7<italic>a</italic>\n<sub>Cl<sup>\u2013</sup>\n</sub>\n<sup>2</sup>. As shown by this equation, considering a constant solubility product\nat a given temperature, and a constant water activity (solvent), the\namount of Piracetam (and hence cocrystal) that is soluble in solution\nis directly impacted by the concentrations of both Ca<sup>2+</sup> and Cl<sup>\u2013</sup> in solution, even those not coming from\ncocrystalline material, the so-called common ion effect. Such a solubility\nproduct is a direct extension of the solubility product discussed\nby Rodriguez-Hornedo and co-workers. They found that such a simplified\nsolubility product is often too simplistic to describe the entire\nsystem, in particular when strong solution interactions between cocrystal\npartners occur. In this study, we therefore\nlimited to an experimental evaluation of the common ion effect of\nthe Cl<sup>\u2013</sup> ion. We thus decided to recreate the ternary\nphase diagram shown in  working with a 30 g\u00b7L<sup>\u20131</sup> concentration\nof NaCl water solution. Such a solution contains 1.025 mol\u00b7L<sup>\u20131</sup> of Cl<sup>\u2013</sup>, which according to the\nsolubility product definition is supposed to have a non-negligible\nimpact on the amount of cocrystal able to dissolve in solution ().</p>", "clean_text": "Ionic Cocrystallization and the Common Ion Effect\n\nContrary to cocrystallization between two organic components, using an inorganic salt as a coformer introduces a supplementary parameter that can be used to fine-tune process conditions and that, as a consequence, needs to be taken into account. Working with a polar solvent, the inorganic salt dissociates in solution into its composing ions. By doing so, a common ion effect due to ions initially present in the solvent could occur. Using the most simplistic model for cocrystal solubility, the cocrystal solubility product can be described as K sp = a pi 2\u22c5a CaCl2 \u22c5a H20 2 ~ a pi 2\u22c5a Ca2+ \u22c5a Cl-  2. As shown by this equation, considering a constant solubility product at a given temperature, and a constant water activity (solvent), the amount of Piracetam (and hence cocrystal) that is soluble in solution is directly impacted by the concentrations of both Ca2+ and Cl- in solution, even those not coming from cocrystalline material, the so-called common ion effect. Such a solubility product is a direct extension of the solubility product discussed by Rodriguez-Hornedo and co-workers. They found that such a simplified solubility product is often too simplistic to describe the entire system, in particular when strong solution interactions between cocrystal partners occur. In this study, we therefore limited to an experimental evaluation of the common ion effect of the Cl- ion. We thus decided to recreate the ternary phase diagram shown in  working with a 30 g\u22c5L-1 concentration of NaCl water solution. Such a solution contains 1.025 mol\u22c5L-1 of Cl-, which according to the solubility product definition is supposed to have a non-negligible impact on the amount of cocrystal able to dissolve in solution ().", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 29, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl4\" position=\"float\">\n<label>4</label>\n<caption>\n<title>Initial Experimental Data for System\nof Piracetam-CaCl<sub>2</sub> in 30 g\u00b7L<sup>\u20131</sup> NaCl\nAqueous Solution at 298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"8\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col8\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col4\" namest=\"col2\" rowsep=\"1\">initial\ncomponents</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col7\" namest=\"col5\" rowsep=\"1\">initial\ncomponents (mol\u00a0%)</oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">solvent (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">solvent</oasis:entry>\n<oasis:entry align=\"center\">solid phase at equilibrium<xref ref-type=\"table-fn\" rid=\"t4fn1\"></xref>\n</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.153</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.847</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.141</oasis:entry>\n<oasis:entry>0.016</oasis:entry>\n<oasis:entry>0.844</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.127</oasis:entry>\n<oasis:entry>0.032</oasis:entry>\n<oasis:entry>0.841</oasis:entry>\n<oasis:entry>Pi\u00a0+\u00a0CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.114</oasis:entry>\n<oasis:entry>0.049</oasis:entry>\n<oasis:entry>0.838</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.099</oasis:entry>\n<oasis:entry>0.066</oasis:entry>\n<oasis:entry>0.834</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.085</oasis:entry>\n<oasis:entry>0.084</oasis:entry>\n<oasis:entry>0.831</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.069</oasis:entry>\n<oasis:entry>0.104</oasis:entry>\n<oasis:entry>0.827</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.053</oasis:entry>\n<oasis:entry>0.123</oasis:entry>\n<oasis:entry>0.824</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.036</oasis:entry>\n<oasis:entry>0.144</oasis:entry>\n<oasis:entry>0.820</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.018</oasis:entry>\n<oasis:entry>0.166</oasis:entry>\n<oasis:entry>0.816</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.188</oasis:entry>\n<oasis:entry>0.812</oasis:entry>\n<oasis:entry>CaCl<sub>2</sub>\n</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t4fn1\">\n<label>a</label>\n<p>pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 30, "type": "text", "classification": "error", "content": "<p>As shown by , there is a clear common ion effect on the phase behavior of an\nionic cocrystal. First of all, one already notices a strong effect\non the solubility of piracetam, which decreases from 1.02 g\u00b7mL<sup>\u20131</sup> to 0.76 g\u00b7mL<sup>\u20131</sup>, which can\nbe seen as a salting out effect. The second one observes a more than\n50% reduction of the solubility of CaCl<sub>2</sub> (from 1.0 to 0.42g.ml<sup>\u20131</sup>), due to the common ion effect of Cl<sup>\u2013</sup>. There is also a strong decrease in the solubility of the cocrystal\nfrom 0.95 g\u00b7mL<sup>\u20131</sup> to 0.63 g\u00b7mL<sup>\u20131</sup>, as would be expected (). Finally, we highlight that the zone wherein the cocrystal\nremains the only stable phase in suspension remains rather large.</p>", "clean_text": "As shown by , there is a clear common ion effect on the phase behavior of an ionic cocrystal. First of all, one already notices a strong effect on the solubility of piracetam, which decreases from 1.02 g\u22c5mL-1 to 0.76 g\u22c5mL-1, which can be seen as a salting out effect. The second one observes a more than 50% reduction of the solubility of CaCl2 (from 1.0 to 0.42g.ml-1), due to the common ion effect of Cl-. There is also a strong decrease in the solubility of the cocrystal from 0.95 g\u22c5mL-1 to 0.63 g\u22c5mL-1, as would be expected (). Finally, we highlight that the zone wherein the cocrystal remains the only stable phase in suspension remains rather large.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else]"}}, {"idx": 31, "type": "table", "classification": null, "content": "<table-wrap id=\"tbl5\" position=\"float\">\n<label>5</label>\n<caption>\n<title>Experimental Data for Dissolution\nPoints in 30 g\u00b7L<sup>\u20131</sup> NaCl Aqueous Solution at\n298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"9\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col8\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col9\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col6\" namest=\"col4\" rowsep=\"1\">components\nat dissolution point</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col9\" namest=\"col7\" rowsep=\"1\">components\nat dissolution point (mol\u00a0%)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">amount of solvent added (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">total amount of solvent (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">solvent (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">solvent</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>61</oasis:entry>\n<oasis:entry>131</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>131</oasis:entry>\n<oasis:entry>0.088</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.912</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>55</oasis:entry>\n<oasis:entry>125</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>125</oasis:entry>\n<oasis:entry>0.085</oasis:entry>\n<oasis:entry>0.009</oasis:entry>\n<oasis:entry>0.906</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>58</oasis:entry>\n<oasis:entry>128</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>128</oasis:entry>\n<oasis:entry>0.075</oasis:entry>\n<oasis:entry>0.019</oasis:entry>\n<oasis:entry>0.906</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>94</oasis:entry>\n<oasis:entry>164</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>164</oasis:entry>\n<oasis:entry>0.054</oasis:entry>\n<oasis:entry>0.023</oasis:entry>\n<oasis:entry>0.923</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>127</oasis:entry>\n<oasis:entry>197</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>197</oasis:entry>\n<oasis:entry>0.040</oasis:entry>\n<oasis:entry>0.026</oasis:entry>\n<oasis:entry>0.934</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>152</oasis:entry>\n<oasis:entry>222</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>222</oasis:entry>\n<oasis:entry>0.030</oasis:entry>\n<oasis:entry>0.030</oasis:entry>\n<oasis:entry>0.940</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>173</oasis:entry>\n<oasis:entry>243</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>243</oasis:entry>\n<oasis:entry>0.023</oasis:entry>\n<oasis:entry>0.034</oasis:entry>\n<oasis:entry>0.943</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>192</oasis:entry>\n<oasis:entry>262</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>262</oasis:entry>\n<oasis:entry>0.016</oasis:entry>\n<oasis:entry>0.038</oasis:entry>\n<oasis:entry>0.946</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>203</oasis:entry>\n<oasis:entry>273</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>273</oasis:entry>\n<oasis:entry>0.011</oasis:entry>\n<oasis:entry>0.043</oasis:entry>\n<oasis:entry>0.947</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>193</oasis:entry>\n<oasis:entry>263</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>263</oasis:entry>\n<oasis:entry>0.006</oasis:entry>\n<oasis:entry>0.051</oasis:entry>\n<oasis:entry>0.943</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>163</oasis:entry>\n<oasis:entry>233</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>233</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.065</oasis:entry>\n<oasis:entry>0.935</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 32, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig5\" position=\"float\">\n<label>5</label>\n<caption>\n<p>TPD zoom picture of piracetam-CaCl<sub>2</sub> in H<sub>2</sub>O and NaCl aqueous solution at 298.15 K (mol %). The green one is\nin H<sub>2</sub>O, and the red one is in NaCl aqueous solution.</p>\n</caption>\n<graphic id=\"gr6\" position=\"float\" xlink:href=\"cg-2018-00352c_0005.tif\"></graphic>\n</fig>", "clean_text": " 5  TPD zoom picture of piracetam-CaCl2 in H2O and NaCl aqueous solution at 298.15 K (mol %). The green one is in H2O, and the red one is in NaCl aqueous solution.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 33, "type": "text", "classification": ["else"], "content": "<title>Conclusion</title><p>In\nthis contribution, we developed a robust, water-based cocrystallization\nprocess for an ionic cocrystal, choosing piracetam-CaCl<sub>2</sub> as the model system. TGA, DSC, and VT-XRPD confirmed the dihydrated\ncocrystal Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O to be stable up to 135 \u00b0C. With water as a solvent,\na ternary phase diagram was developed showing a rather large congruent\nzone with the cocrystal as only stable phase in suspension. Based\non this diagram, we developed an upscaled process for the manufacturing\nof Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O. Finally, we illustrated the importance of the common ion effect\non the crystallization of ICCs.</p>", "clean_text": "Conclusion\n\nIn this contribution, we developed a robust, water-based cocrystallization process for an ionic cocrystal, choosing piracetam-CaCl2 as the model system. TGA, DSC, and VT-XRPD confirmed the dihydrated cocrystal Piracetam2\u22c5CaCl2\u22c52H2O to be stable up to 135 \u00b0C. With water as a solvent, a ternary phase diagram was developed showing a rather large congruent zone with the cocrystal as only stable phase in suspension. Based on this diagram, we developed an upscaled process for the manufacturing of Piracetam2\u22c5CaCl2\u22c52H2O. Finally, we illustrated the importance of the common ion effect on the crystallization of ICCs.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 34, "type": "text", "classification": ["else"], "content": "<p>The Supporting Information\nis available free of charge on the <ext-link xlink:href=\"http://pubs.acs.org\">ACS Publications website</ext-link> at DOI: <ext-link xlink:href=\"http://pubs.acs.org/doi/abs/10.1021/acs.cgd.8b00352\">10.1021/acs.cgd.8b00352</ext-link>.<list id=\"silist\" list-type=\"label\">\n<list-item>\n<p>TGA and DSC curves,\nVT-XRPD, additional experimental\ndata, and TPD images (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">PDF</ext-link>)</p>\n</list-item>\n</list>\n</p>", "clean_text": "The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.cgd.8b00352.  TGA and DSC curves, VT-XRPD, additional experimental data, and TPD images (PDF)   ", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 35, "type": "text", "classification": ["else"], "content": "<p>TGA and DSC curves,\nVT-XRPD, additional experimental\ndata, and TPD images (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">PDF</ext-link>)</p><p>CCDC <ext-link ext-link-type=\"ccdc\" xlink:href=\"1827949\">1827949</ext-link> contains the supplementary crystallographic data\nfor this paper. These data can be obtained free of charge via <ext-link xlink:href=\"http://www.ccdc.cam.ac.uk/data_request/cif\">www.ccdc.cam.ac.uk/data_request/cif</ext-link>, or by emailing <email>data_request@ccdc.cam.ac.uk</email>, or by\ncontacting The Cambridge Crystallographic Data Centre, 12 Union Road,\nCambridge CB2 1EZ, UK; fax: +44 1223 336033.</p>", "clean_text": "TGA and DSC curves, VT-XRPD, additional experimental data, and TPD images (PDF)\n\nCCDC 1827949 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}, {"idx": 36, "type": "text", "classification": ["else"], "content": "<p>The authors declare no\ncompeting financial interest.</p>", "clean_text": "The authors declare no competing financial interest.", "data": null, "include_properties": null, "intermediate_step": {"categorize": "['else']"}}], "cln_elements": [{"idx": "7, 27", "type": "text", "classification": "synthesis condition", "content": "<title>Single Crystal\nSynthesis</title><p>An equimolar mixture of Piracetam\n(14.2 mg, 1.00 mmol) and CaCl<sub>2</sub> (11.1 mg, 1.00 mmol) was\ndissolved in ethanol (2 mL) and left to evaporate over 3 days to get\nsuitable crystals for single crystal diffraction. Single crystals\nof piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O were obtained, as confirmed by single crystal X-ray diffraction\nand powder diffraction experiments.</p><p>Based on the TPD,\na solution cocrystallization process was suggested\nstarting with a stoichiometric amount of starting compounds. 15 g\nof piracetam and 5.86 g of CaCl<sub>2</sub> (0.5 equiv) were added\nto 18 mL of water. This corresponds to the large red dot shown in . By heating to 75\n\u00b0C all solid forms were dissolved, and under continuous stirring\nthe solution was then brought back to 25 \u00b0C, by removing the\nsolution from its 75 \u00b0C environment and placing it in a surrounding\nof 25 \u00b0C. Crystallization occurred spontaneously during cooling.\nHowever, to ensure that the thermodynamically stable cocrystal phase\nwas obtained, cocrystal seeding material was added, and the suspension\nleft to stir for 3 h. The suspension was then filtered, and the powder\nleft to dry. 5.80 g of dried cocrystal material was recovered, and\nshown to correspond to the dihydrate cocrystal phase (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S7</ext-link>) by XRPD of the bulk material. This\ncorresponds to a 25% yield, in alignment with the maximum theoretical\nyield of 29%, based on the TPD data. As mentioned above, the yield\ncan be increased optimizing the process conditions (amount of water,\nchanging the temperature, recycling the filtrate which contains a\nstoichiometric ration of CaCl<sub>2</sub> and piracetam), but this\ngoes beyond the scope of the current contribution.</p>", "clean_text": "Single Crystal Synthesis\n\nAn equimolar mixture of Piracetam (14.2 mg, 1.00 mmol) and CaCl2 (11.1 mg, 1.00 mmol) was dissolved in ethanol (2 mL) and left to evaporate over 3 days to get suitable crystals for single crystal diffraction. Single crystals of piracetam2\u22c5CaCl2\u22c52H2O were obtained, as confirmed by single crystal X-ray diffraction and powder diffraction experiments.\n\nBased on the TPD, a solution cocrystallization process was suggested starting with a stoichiometric amount of starting compounds. 15 g of piracetam and 5.86 g of CaCl2 (0.5 equiv) were added to 18 mL of water. This corresponds to the large red dot shown in . By heating to 75 \u00b0C all solid forms were dissolved, and under continuous stirring the solution was then brought back to 25 \u00b0C, by removing the solution from its 75 \u00b0C environment and placing it in a surrounding of 25 \u00b0C. Crystallization occurred spontaneously during cooling. However, to ensure that the thermodynamically stable cocrystal phase was obtained, cocrystal seeding material was added, and the suspension left to stir for 3 h. The suspension was then filtered, and the powder left to dry. 5.80 g of dried cocrystal material was recovered, and shown to correspond to the dihydrate cocrystal phase (Figure S7) by XRPD of the bulk material. This corresponds to a 25% yield, in alignment with the maximum theoretical yield of 29%, based on the TPD data. As mentioned above, the yield can be increased optimizing the process conditions (amount of water, changing the temperature, recycling the filtrate which contains a stoichiometric ration of CaCl2 and piracetam), but this goes beyond the scope of the current contribution.", "data": [[{"meta": {"name": "piracetam2\u22c5CaCl2\u22c52H2O", "symbol": "", "chemical formula": ""}, "processes": [{"synthesis method": "chemical synthesis", "precursor": [{"name": "Piracetam", "amount": "14.2", "unit": "mg"}, {"name": "CaCl2", "amount": "11.1", "unit": "mg"}], "solution": [{"name": "ethanol", "amount": "2", "unit": "mL"}], "pressure": "", "temperature": "", "time": "3 days"}], "yield": ""}, {"meta": {"name": "piracetam2\u22c5CaCl2\u22c52H2O", "symbol": "", "chemical formula": ""}, "processes": [{"synthesis method": "chemical synthesis", "precursor": [{"name": "piracetam", "amount": "15", "unit": "g"}, {"name": "CaCl2", "amount": "5.86", "unit": "g"}], "solution": [{"name": "water", "amount": "18", "unit": "mL"}], "pressure": "", "temperature": "75 \u00b0C to 25 \u00b0C", "time": "3 h"}, {"synthesis method": "seeding", "seed material": "cocrystal seeding material", "time": "3 h"}, {"synthesis method": "filtration", "time": "", "atmosphere": "", "pressure": ""}, {"synthesis method": "drying", "pressure": "", "temperature": "", "atmosphere": "", "time": ""}], "yield": "25%"}]], "include_properties": ["drying", "filtration", "chemical_synthesis"], "intermediate_step": {"text-synthesis-type": "['chemical_synthesis', 'filtration', 'drying']", "text-synthesis-struct": "```JSON\n[{\"meta\":{\"name\":\"piracetam2\u22c5CaCl2\u22c52H2O\", \"symbol\":\"\", \"chemical formula\":\"\"}, \"processes\":[{\"synthesis method\":\"chemical synthesis\", \"precursor\":[{\"name\":\"Piracetam\", \"amount\":\"14.2\", \"unit\":\"mg\"}, {\"name\":\"CaCl2\", \"amount\":\"11.1\", \"unit\":\"mg\"}], \"solution\":[{\"name\":\"ethanol\", \"amount\":\"2\", \"unit\":\"mL\"}], \"pressure\":\"\", \"temperature\":\"\", \"time\":\"3 days\"}], \"yield\":\"\"}, {\"meta\":{\"name\":\"piracetam2\u22c5CaCl2\u22c52H2O\", \"symbol\":\"\", \"chemical formula\":\"\"}, \"processes\":[{\"synthesis method\":\"chemical synthesis\", \"precursor\":[{\"name\":\"piracetam\", \"amount\":\"15\", \"unit\":\"g\"}, {\"name\":\"CaCl2\", \"amount\":\"5.86\", \"unit\":\"g\"}], \"solution\":[{\"name\":\"water\", \"amount\":\"18\", \"unit\":\"mL\"}], \"pressure\":\"\", \"temperature\":\"75 \u00b0C to 25 \u00b0C\", \"time\":\"3 h\"}, {\"synthesis method\":\"seeding\", \"seed material\":\"cocrystal seeding material\", \"time\":\"3 h\"}, {\"synthesis method\":\"filtration\", \"time\":\"\", \"atmosphere\":\"\", \"pressure\":\"\"}, {\"synthesis method\":\"drying\", \"pressure\":\"\", \"temperature\":\"\", \"atmosphere\":\"\", \"time\":\"\"}], \"yield\":\"25%\"}]\n```"}}, {"idx": 21, "type": "text", "classification": "property", "content": "<title>Thermal Stability</title><p>TGA analysis (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S1</ext-link>) shows a 7.6% weight loss between 140 and 160 \u00b0C,\ncorresponding to the loss of 2 equiv of water (theoretical wt% = 8.36).\nTGA analysis indicates a single step water loss. DSC analysis (<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S2</ext-link>) confirms the water loss at 140 \u00b0C\nas seen by the large endothermic signal. Variable-temperature XRPD\n(<ext-link xlink:href=\"http://pubs.acs.org/doi/suppl/10.1021/acs.cgd.8b00352/suppl_file/cg8b00352_si_001.pdf\">Figure S3</ext-link>) was used to highlight the one-step\ndehydration to an anhydrate solid phase at 140 \u00b0C, leading to\na phase which remains unchanged up to 220 \u00b0C. From 240 \u00b0C\nonward, degradation occurs. As piracetam melts at 127 \u00b0C, the ICC allows improvement of the thermal stability\nof piracetam in the solid state.</p>", "clean_text": "Thermal Stability\n\nTGA analysis (Figure S1) shows a 7.6% weight loss between 140 and 160 \u00b0C, corresponding to the loss of 2 equiv of water (theoretical wt% = 8.36). TGA analysis indicates a single step water loss. DSC analysis (Figure S2) confirms the water loss at 140 \u00b0C as seen by the large endothermic signal. Variable-temperature XRPD (Figure S3) was used to highlight the one-step dehydration to an anhydrate solid phase at 140 \u00b0C, leading to a phase which remains unchanged up to 220 \u00b0C. From 240 \u00b0C onward, degradation occurs. As piracetam melts at 127 \u00b0C, the ICC allows improvement of the thermal stability of piracetam in the solid state.", "data": [[[{"meta": {"name": "piracetam", "symbol": "", "chemical formula": ""}, "decomposition temperature": [{"value": "140 to 160", "unit": "\u00b0C", "type": "weight loss", "condition": "loss of 2 equiv of water"}, {"value": "140", "unit": "\u00b0C", "type": "dehydration", "condition": "transition to an anhydrate solid phase"}, {"value": "220", "unit": "\u00b0C", "type": "stable", "condition": "phase remains unchanged"}, {"value": "240", "unit": "\u00b0C", "type": "degradation", "condition": ""}]}]]], "include_properties": ["decomposition_temperature"], "intermediate_step": {"categorize": "['property']", "text-property-type": "['decomposition_temperature']", "text-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"piracetam\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\"\n        },\n        \"decomposition temperature\": [\n            {\n                \"value\": \"140 to 160\",\n                \"unit\": \"\u00b0C\",\n                \"type\": \"weight loss\",\n                \"condition\": \"loss of 2 equiv of water\"\n            },\n            {\n                \"value\": \"140\",\n                \"unit\": \"\u00b0C\",\n                \"type\": \"dehydration\",\n                \"condition\": \"transition to an anhydrate solid phase\"\n            },\n            {\n                \"value\": \"220\",\n                \"unit\": \"\u00b0C\",\n                \"type\": \"stable\",\n                \"condition\": \"phase remains unchanged\"\n            },\n            {\n                \"value\": \"240\",\n                \"unit\": \"\u00b0C\",\n                \"type\": \"degradation\",\n                \"condition\": \"\"\n            }\n        ]\n    }\n]\n```"}}, {"idx": 20, "type": "table", "classification": ["Crystal"], "content": "<table-wrap id=\"tbl1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Crystallographic\nData of Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"2\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col2\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\">cocrystal piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>empirical formula</oasis:entry>\n<oasis:entry>C<sub>12</sub>H<sub>24</sub>CaCl<sub>2</sub>N<sub>4</sub>O<sub>6</sub>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>M</oasis:entry>\n<oasis:entry>431.33</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>T</italic> [K]</oasis:entry>\n<oasis:entry>296(2)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>crystal system</oasis:entry>\n<oasis:entry>monoclinic</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>space group</oasis:entry>\n<oasis:entry>\n<italic>P</italic>2<sub>1</sub>/<italic>n</italic>\n</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>a</italic> [\u00c5]</oasis:entry>\n<oasis:entry>8.9057(4)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>b</italic> [\u00c5]</oasis:entry>\n<oasis:entry>9.6203(4)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>c</italic> [\u00c5]</oasis:entry>\n<oasis:entry>11.9399(5)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b2 [\u00b0]</oasis:entry>\n<oasis:entry>108.077(4)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>V [\u00c5<sup>3</sup>]</oasis:entry>\n<oasis:entry>972.47(7)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>Z</italic>\n</oasis:entry>\n<oasis:entry>2</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03c1<sub>calcd</sub> [Mg m<sup>\u20133</sup>]</oasis:entry>\n<oasis:entry>1.473</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>F</italic> (000)</oasis:entry>\n<oasis:entry>452</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03bc [mm<sup>\u20131</sup>]</oasis:entry>\n<oasis:entry>0.632</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>crystal size [mm]</oasis:entry>\n<oasis:entry>0.48 \u00d7 0.40\n\u00d7 0.15</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\u03b8 range (deg)</oasis:entry>\n<oasis:entry>3.205 to 26.012\u00b0</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>reflection collected/unique</oasis:entry>\n<oasis:entry>6845/1861</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>\n<italic>R</italic>\n<sub>int</sub>\n</oasis:entry>\n<oasis:entry>0.0377</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>GoF</oasis:entry>\n<oasis:entry>1.006</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>Threshold expression</oasis:entry>\n<oasis:entry>&gt;2\u03c3(I)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>R1 (obsd)</oasis:entry>\n<oasis:entry>0.0344</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>wR2\n(all)</oasis:entry>\n<oasis:entry>0.0805</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "Table 1. Crystallographic Data of Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O\n\n|                    | cocrystal piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O |\n|--------------------|--------------------------------------------------------------|\n| empirical formula | C<sub>12</sub>H<sub>24</sub>CaCl<sub>2</sub>N<sub>4</sub>O<sub>6</sub> |\n| M                  | 431.33                                                       |\n| T [K]              | 296(2)                                                       |\n| crystal system    | monoclinic                                                   |\n| space group       | P2<sub>1</sub>/n                                              |\n| a [\u00c5]              | 8.9057(4)                                                    |\n| b [\u00c5]              | 9.6203(4)                                                    |\n| c [\u00c5]              | 11.9399(5)                                                   |\n| \u03b2 [\u00b0]              | 108.077(4)                                                   |\n| V [\u00c5<sup>3</sup>] | 972.47(7)                                                    |\n| Z                  | 2                                                            |\n| \u03c1<sub>calcd</sub> [Mg m<sup>\u20133</sup>] | 1.473                                  |\n| F (000)            | 452                                                          |\n| \u03bc [mm<sup>\u20131</sup>] | 0.632                                                      |\n| crystal size [mm] | 0.48 \u00d7 0.40 \u00d7 0.15                                            |\n| \u03b8 range (deg)      | 3.205 to 26.012\u00b0                                             |\n| reflection collected/unique | 6845/1861                                      |\n| R<sub>int</sub>   | 0.0377                                                       |\n| GoF                | 1.006                                                        |\n| Threshold expression | &gt;2\u03c3(I)                                                 |\n| R1 (obsd)          | 0.0344                                                       |\n| wR2 (all)          | 0.0805                                                       |", "data": [[{"meta": {"name": "cocrystal piracetam2\u00b7CaCl2\u00b72H2O", "symbol": "", "chemical formula": "C12H24CaCl2N4O6"}, "chemical formula weight": [{"value": "431.33", "unit": "", "condition": ""}], "crystal system": [{"value": "monoclinic", "condition": ""}], "space group": [{"value": "P21/n", "condition": ""}], "lattice parameters": [{"value": {"a": "8.9057(4)", "b": "9.6203(4)", "c": "11.9399(5)", "alpha": "", "beta": "108.077(4)", "gamma": ""}, "condition": ""}], "cell volume": [{"value": "972.47(7)", "unit": "\u00c5^3", "condition": ""}], "density": [{"value": "1.473", "unit": "Mg m^\u20133", "condition": ""}], "crystal size": [{"value": "0.48 x 0.40 x 0.15", "unit": "mm", "condition": ""}]}]], "include_properties": ["chemical_formula", "chemical_formula_weight", "crystal_system", "space_group", "lattice_parameters", "cell_volume", "density", "crystal_size"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 1. Crystallographic Data of Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O\n\n|                    | cocrystal piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O |\n|--------------------|--------------------------------------------------------------|\n| empirical formula | C<sub>12</sub>H<sub>24</sub>CaCl<sub>2</sub>N<sub>4</sub>O<sub>6</sub> |\n| M                  | 431.33                                                       |\n| T [K]              | 296(2)                                                       |\n| crystal system    | monoclinic                                                   |\n| space group       | P2<sub>1</sub>/n                                              |\n| a [\u00c5]              | 8.9057(4)                                                    |\n| b [\u00c5]              | 9.6203(4)                                                    |\n| c [\u00c5]              | 11.9399(5)                                                   |\n| \u03b2 [\u00b0]              | 108.077(4)                                                   |\n| V [\u00c5<sup>3</sup>] | 972.47(7)                                                    |\n| Z                  | 2                                                            |\n| \u03c1<sub>calcd</sub> [Mg m<sup>\u20133</sup>] | 1.473                                  |\n| F (000)            | 452                                                          |\n| \u03bc [mm<sup>\u20131</sup>] | 0.632                                                      |\n| crystal size [mm] | 0.48 \u00d7 0.40 \u00d7 0.15                                            |\n| \u03b8 range (deg)      | 3.205 to 26.012\u00b0                                             |\n| reflection collected/unique | 6845/1861                                      |\n| R<sub>int</sub>   | 0.0377                                                       |\n| GoF                | 1.006                                                        |\n| Threshold expression | &gt;2\u03c3(I)                                                 |\n| R1 (obsd)          | 0.0344                                                       |\n| wR2 (all)          | 0.0805                                                       |\n<END>", "table-categorize": "Crystal", "table-crystal-categorize": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"cocrystal piracetam2\u00b7CaCl2\u00b72H2O\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"C12H24CaCl2N4O6\",\n        },\n        \"chemical formula weight\": [\n            {\n                \"value\": \"431.33\",\n                \"unit\": \"\",\n                \"condition\": \"\",\n            },\n        ],\n        \"crystal system\": [\n            {\n                \"value\": \"monoclinic\",\n                \"condition\": \"\",\n            },\n        ],\n        \"space group\": [\n            {\n                \"value\": \"P21/n\",\n                \"condition\": \"\",\n            },\n        ],\n        \"lattice parameters\": [\n            {\n                \"value\": {\n                    \"a\": \"8.9057(4)\",\n                    \"b\": \"9.6203(4)\",\n                    \"c\": \"11.9399(5)\",\n                    \"alpha\": \"\",\n                    \"beta\": \"108.077(4)\",\n                    \"gamma\": \"\",\n                },\n                \"condition\": \"\",\n            },\n        ],\n        \"cell volume\": [\n            {\n                \"value\": \"972.47(7)\",\n                \"unit\": \"\u00c5^3\",\n                \"condition\": \"\",\n            },\n        ],\n        \"density\": [\n            {\n                \"value\": \"1.473\",\n                \"unit\": \"Mg m^\u20133\",\n                \"condition\": \"\",\n            },\n        ],\n        \"crystal size\": [\n            {\n                \"value\": \"0.48 x 0.40 x 0.15\",\n                \"unit\": \"mm\",\n                \"condition\": \"\",\n            },\n        ],\n    },\n]\n```"}}, {"idx": 23, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"tbl2\" position=\"float\">\n<label>2</label>\n<caption>\n<title>Initial\nExperimental Data for System\nof Water-Piracetam-CaCl<sub>2</sub> at 298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"8\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col8\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col4\" namest=\"col2\" rowsep=\"1\">initial\ncomponents</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col7\" namest=\"col5\" rowsep=\"1\">initial\ncomponents (mol\u00a0%)</oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O</oasis:entry>\n<oasis:entry align=\"center\">solid phase at equilibrium<xref ref-type=\"table-fn\" rid=\"t2fn1\"></xref>\n</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.202</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.798</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.185</oasis:entry>\n<oasis:entry>0.021</oasis:entry>\n<oasis:entry>0.794</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.168</oasis:entry>\n<oasis:entry>0.042</oasis:entry>\n<oasis:entry>0.790</oasis:entry>\n<oasis:entry>Pi\u00a0+\u00a0CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.150</oasis:entry>\n<oasis:entry>0.064</oasis:entry>\n<oasis:entry>0.786</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0.131</oasis:entry>\n<oasis:entry>0.087</oasis:entry>\n<oasis:entry>0.782</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.062</oasis:entry>\n<oasis:entry>0.062</oasis:entry>\n<oasis:entry>0.875</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.051</oasis:entry>\n<oasis:entry>0.076</oasis:entry>\n<oasis:entry>0.873</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.039</oasis:entry>\n<oasis:entry>0.091</oasis:entry>\n<oasis:entry>0.870</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.027</oasis:entry>\n<oasis:entry>0.107</oasis:entry>\n<oasis:entry>0.867</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0.014</oasis:entry>\n<oasis:entry>0.123</oasis:entry>\n<oasis:entry>0.864</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>50</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.245</oasis:entry>\n<oasis:entry>0.755</oasis:entry>\n<oasis:entry>CaCl<sub>2</sub>\n</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t2fn1\">\n<label>a</label>\n<p>Pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "Table 2. Initial Experimental Data for System of Water-Piracetam-CaCl<sub>2</sub> at 298.15 K\n\n| sample no. | initial components | initial components (mol\u00a0%) |  |  |  |  | solid phase at equilibrium[^a] |\n|------------|---------------------|-----------------------------|---|---|---|---|--------------------------------|\n|            | piracetam (mg)      | CaCl<sub>2</sub> (mg)        | H<sub>2</sub>O (\u03bcL) | piracetam | CaCl<sub>2</sub> | H<sub>2</sub>O |                                  |\n| 1          | 100                 | 0                           | 50                 | 0.202     | 0               | 0.798         | Pi                               |\n| 2          | 92.02               | 7.98                        | 50                 | 0.185     | 0.021           | 0.794         | Pi                               |\n| 3          | 83.67               | 16.33                       | 50                 | 0.168     | 0.042           | 0.790         | Pi\u00a0+\u00a0CC                          |\n| 4          | 74.93               | 25.07                       | 50                 | 0.150     | 0.064           | 0.786         | CC                               |\n| 5          | 65.77               | 34.23                       | 50                 | 0.131     | 0.087           | 0.782         | CC                               |\n| 6          | 56.16               | 43.84                       | 100                | 0.062     | 0.062           | 0.875         | CC                               |\n| 7          | 46.06               | 53.94                       | 100                | 0.051     | 0.076           | 0.873         | CC                               |\n| 8          | 35.44               | 64.56                       | 100                | 0.039     | 0.091           | 0.870         | CC                               |\n| 9          | 24.26               | 75.74                       | 100                | 0.027     | 0.107           | 0.867         | CC                               |\n| 10         | 12.46               | 87.54                       | 100                | 0.014     | 0.123           | 0.864         | CC                               |\n| 11         | 0                   | 100                         | 50                 | 0         | 0.245           | 0.755         | CaCl<sub>2</sub>                  |\n\n[^a]: Pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.", "data": [[{"meta": {"name": "Water-Piracetam-CaCl2 System", "symbol": "", "chemical formula": "H2O-C6H10N2O2-CaCl2"}, "etc": [{"property name": "solid phase at equilibrium", "value": "Pi", "unit": "", "condition": "sample no. 1, initial components: piracetam 100 mg, CaCl2 0 mg, H2O 50 \u03bcL, mol%: piracetam 0.202, CaCl2 0, H2O 0.798"}, {"property name": "solid phase at equilibrium", "value": "Pi", "unit": "", "condition": "sample no. 2, initial components: piracetam 92.02 mg, CaCl2 7.98 mg, H2O 50 \u03bcL, mol%: piracetam 0.185, CaCl2 0.021, H2O 0.794"}, {"property name": "solid phase at equilibrium", "value": "Pi + CC", "unit": "", "condition": "sample no. 3, initial components: piracetam 83.67 mg, CaCl2 16.33 mg, H2O 50 \u03bcL, mol%: piracetam 0.168, CaCl2 0.042, H2O 0.790"}, {"property name": "solid phase at equilibrium", "value": "CC", "unit": "", "condition": "sample no. 4, initial components: piracetam 74.93 mg, CaCl2 25.07 mg, H2O 50 \u03bcL, mol%: piracetam 0.150, CaCl2 0.064, H2O 0.786"}, {"property name": "solid phase at equilibrium", "value": "CC", "unit": "", "condition": "sample no. 5, initial components: piracetam 65.77 mg, CaCl2 34.23 mg, H2O 50 \u03bcL, mol%: piracetam 0.131, CaCl2 0.087, H2O 0.782"}, {"property name": "solid phase at equilibrium", "value": "CC", "unit": "", "condition": "sample no. 6, initial components: piracetam 56.16 mg, CaCl2 43.84 mg, H2O 100 \u03bcL, mol%: piracetam 0.062, CaCl2 0.062, H2O 0.875"}, {"property name": "solid phase at equilibrium", "value": "CC", "unit": "", "condition": "sample no. 7, initial components: piracetam 46.06 mg, CaCl2 53.94 mg, H2O 100 \u03bcL, mol%: piracetam 0.051, CaCl2 0.076, H2O 0.873"}, {"property name": "solid phase at equilibrium", "value": "CC", "unit": "", "condition": "sample no. 8, initial components: piracetam 35.44 mg, CaCl2 64.56 mg, H2O 100 \u03bcL, mol%: piracetam 0.039, CaCl2 0.091, H2O 0.870"}, {"property name": "solid phase at equilibrium", "value": "CC", "unit": "", "condition": "sample no. 9, initial components: piracetam 24.26 mg, CaCl2 75.74 mg, H2O 100 \u03bcL, mol%: piracetam 0.027, CaCl2 0.107, H2O 0.867"}, {"property name": "solid phase at equilibrium", "value": "CC", "unit": "", "condition": "sample no. 10, initial components: piracetam 12.46 mg, CaCl2 87.54 mg, H2O 100 \u03bcL, mol%: piracetam 0.014, CaCl2 0.123, H2O 0.864"}, {"property name": "solid phase at equilibrium", "value": "CaCl2", "unit": "", "condition": "sample no. 11, initial components: piracetam 0 mg, CaCl2 100 mg, H2O 50 \u03bcL, mol%: piracetam 0, CaCl2 0.245, H2O 0.755"}]}]], "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 2. Initial Experimental Data for System of Water-Piracetam-CaCl<sub>2</sub> at 298.15 K\n\n| sample no. | initial components | initial components (mol\u00a0%) |  |  |  |  | solid phase at equilibrium[^a] |\n|------------|---------------------|-----------------------------|---|---|---|---|--------------------------------|\n|            | piracetam (mg)      | CaCl<sub>2</sub> (mg)        | H<sub>2</sub>O (\u03bcL) | piracetam | CaCl<sub>2</sub> | H<sub>2</sub>O |                                  |\n| 1          | 100                 | 0                           | 50                 | 0.202     | 0               | 0.798         | Pi                               |\n| 2          | 92.02               | 7.98                        | 50                 | 0.185     | 0.021           | 0.794         | Pi                               |\n| 3          | 83.67               | 16.33                       | 50                 | 0.168     | 0.042           | 0.790         | Pi\u00a0+\u00a0CC                          |\n| 4          | 74.93               | 25.07                       | 50                 | 0.150     | 0.064           | 0.786         | CC                               |\n| 5          | 65.77               | 34.23                       | 50                 | 0.131     | 0.087           | 0.782         | CC                               |\n| 6          | 56.16               | 43.84                       | 100                | 0.062     | 0.062           | 0.875         | CC                               |\n| 7          | 46.06               | 53.94                       | 100                | 0.051     | 0.076           | 0.873         | CC                               |\n| 8          | 35.44               | 64.56                       | 100                | 0.039     | 0.091           | 0.870         | CC                               |\n| 9          | 24.26               | 75.74                       | 100                | 0.027     | 0.107           | 0.867         | CC                               |\n| 10         | 12.46               | 87.54                       | 100                | 0.014     | 0.123           | 0.864         | CC                               |\n| 11         | 0                   | 100                         | 50                 | 0         | 0.245           | 0.755         | CaCl<sub>2</sub>                  |\n\n[^a]: Pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"Water-Piracetam-CaCl2 System\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"H2O-C6H10N2O2-CaCl2\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"Pi\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 1, initial components: piracetam 100 mg, CaCl2 0 mg, H2O 50 \u03bcL, mol%: piracetam 0.202, CaCl2 0, H2O 0.798\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"Pi\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 2, initial components: piracetam 92.02 mg, CaCl2 7.98 mg, H2O 50 \u03bcL, mol%: piracetam 0.185, CaCl2 0.021, H2O 0.794\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"Pi + CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 3, initial components: piracetam 83.67 mg, CaCl2 16.33 mg, H2O 50 \u03bcL, mol%: piracetam 0.168, CaCl2 0.042, H2O 0.790\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 4, initial components: piracetam 74.93 mg, CaCl2 25.07 mg, H2O 50 \u03bcL, mol%: piracetam 0.150, CaCl2 0.064, H2O 0.786\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 5, initial components: piracetam 65.77 mg, CaCl2 34.23 mg, H2O 50 \u03bcL, mol%: piracetam 0.131, CaCl2 0.087, H2O 0.782\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 6, initial components: piracetam 56.16 mg, CaCl2 43.84 mg, H2O 100 \u03bcL, mol%: piracetam 0.062, CaCl2 0.062, H2O 0.875\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 7, initial components: piracetam 46.06 mg, CaCl2 53.94 mg, H2O 100 \u03bcL, mol%: piracetam 0.051, CaCl2 0.076, H2O 0.873\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 8, initial components: piracetam 35.44 mg, CaCl2 64.56 mg, H2O 100 \u03bcL, mol%: piracetam 0.039, CaCl2 0.091, H2O 0.870\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 9, initial components: piracetam 24.26 mg, CaCl2 75.74 mg, H2O 100 \u03bcL, mol%: piracetam 0.027, CaCl2 0.107, H2O 0.867\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CC\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 10, initial components: piracetam 12.46 mg, CaCl2 87.54 mg, H2O 100 \u03bcL, mol%: piracetam 0.014, CaCl2 0.123, H2O 0.864\",\n            },\n            {\n                \"property name\": \"solid phase at equilibrium\",\n                \"value\": \"CaCl2\",\n                \"unit\": \"\",\n                \"condition\": \"sample no. 11, initial components: piracetam 0 mg, CaCl2 100 mg, H2O 50 \u03bcL, mol%: piracetam 0, CaCl2 0.245, H2O 0.755\",\n            }\n        ],\n    }\n]\n```"}}, {"idx": 24, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"tbl3\" position=\"float\">\n<label>3</label>\n<caption>\n<title>Experimental Data for the Dissolution\nPoints at 298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"9\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col8\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col9\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col6\" namest=\"col4\" rowsep=\"1\">composition\nat dissolution point</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col9\" namest=\"col7\" rowsep=\"1\">composition\nat dissolution point (mol\u00a0%)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">amount of H<sub>2</sub>O added (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">total amount of H<sub>2</sub>O (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O\n(\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">H<sub>2</sub>O</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>48</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>0.115</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.885</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>39</oasis:entry>\n<oasis:entry>89</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>89</oasis:entry>\n<oasis:entry>0.114</oasis:entry>\n<oasis:entry>0.013</oasis:entry>\n<oasis:entry>0.873</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>34</oasis:entry>\n<oasis:entry>84</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>84</oasis:entry>\n<oasis:entry>0.109</oasis:entry>\n<oasis:entry>0.027</oasis:entry>\n<oasis:entry>0.864</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>56</oasis:entry>\n<oasis:entry>106</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>106</oasis:entry>\n<oasis:entry>0.079</oasis:entry>\n<oasis:entry>0.034</oasis:entry>\n<oasis:entry>0.886</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>83</oasis:entry>\n<oasis:entry>133</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>133</oasis:entry>\n<oasis:entry>0.057</oasis:entry>\n<oasis:entry>0.038</oasis:entry>\n<oasis:entry>0.905</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>58</oasis:entry>\n<oasis:entry>158</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>158</oasis:entry>\n<oasis:entry>0.041</oasis:entry>\n<oasis:entry>0.041</oasis:entry>\n<oasis:entry>0.917</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>75</oasis:entry>\n<oasis:entry>175</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>175</oasis:entry>\n<oasis:entry>0.031</oasis:entry>\n<oasis:entry>0.046</oasis:entry>\n<oasis:entry>0.923</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>0.021</oasis:entry>\n<oasis:entry>0.049</oasis:entry>\n<oasis:entry>0.930</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>98</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>198</oasis:entry>\n<oasis:entry>0.014</oasis:entry>\n<oasis:entry>0.058</oasis:entry>\n<oasis:entry>0.928</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>85</oasis:entry>\n<oasis:entry>185</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>185</oasis:entry>\n<oasis:entry>0.008</oasis:entry>\n<oasis:entry>0.071</oasis:entry>\n<oasis:entry>0.921</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>49</oasis:entry>\n<oasis:entry>99</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>99</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.141</oasis:entry>\n<oasis:entry>0.859</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "Table 3. Experimental Data for the Dissolution Points at 298.15 K\n\n| sample no. | amount of H<sub>2</sub>O added (\u03bcL) | total amount of H<sub>2</sub>O (\u03bcL) | piracetam (mg) | CaCl<sub>2</sub> (mg) | H<sub>2</sub>O (\u03bcL) | piracetam | CaCl<sub>2</sub> | H<sub>2</sub>O |\n|------------|----------------------------------|-----------------------------------|----------------|----------------------|-------------------|-----------|-----------------|----------------|\n| 1          | 48                               | 98                                | 100            | 0                    | 98                | 0.115     | 0.000           | 0.885          |\n| 2          | 39                               | 89                                | 92.02          | 7.98                 | 89                | 0.114     | 0.013           | 0.873          |\n| 3          | 34                               | 84                                | 83.67          | 16.33                | 84                | 0.109     | 0.027           | 0.864          |\n| 4          | 56                               | 106                               | 74.93          | 25.07                | 106               | 0.079     | 0.034           | 0.886          |\n| 5          | 83                               | 133                               | 65.77          | 34.23                | 133               | 0.057     | 0.038           | 0.905          |\n| 6          | 58                               | 158                               | 56.16          | 43.84                | 158               | 0.041     | 0.041           | 0.917          |\n| 7          | 75                               | 175                               | 46.06          | 53.94                | 175               | 0.031     | 0.046           | 0.923          |\n| 8          | 98                               | 198                               | 35.44          | 64.56                | 198               | 0.021     | 0.049           | 0.930          |\n| 9          | 98                               | 198                               | 24.26          | 75.74                | 198               | 0.014     | 0.058           | 0.928          |\n| 10         | 85                               | 185                               | 12.46          | 87.54                | 185               | 0.008     | 0.071           | 0.921          |\n| 11         | 49                               | 99                                | 0              | 100                  | 99                | 0.000     | 0.141           | 0.859          |", "data": [[{"meta": {"name": "", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "amount of H2O added", "value": "48", "unit": "\u03bcL", "condition": "sample no. 1, total amount of H2O 98 \u03bcL, piracetam 100 mg, CaCl2 0 mg, H2O 98 \u03bcL, piracetam 0.115, CaCl2 0.000, H2O 0.885 at 298.15 K"}, {"property name": "amount of H2O added", "value": "39", "unit": "\u03bcL", "condition": "sample no. 2, total amount of H2O 89 \u03bcL, piracetam 92.02 mg, CaCl2 7.98 mg, H2O 89 \u03bcL, piracetam 0.114, CaCl2 0.013, H2O 0.873 at 298.15 K"}, {"property name": "amount of H2O added", "value": "34", "unit": "\u03bcL", "condition": "sample no. 3, total amount of H2O 84 \u03bcL, piracetam 83.67 mg, CaCl2 16.33 mg, H2O 84 \u03bcL, piracetam 0.109, CaCl2 0.027, H2O 0.864 at 298.15 K"}, {"property name": "amount of H2O added", "value": "56", "unit": "\u03bcL", "condition": "sample no. 4, total amount of H2O 106 \u03bcL, piracetam 74.93 mg, CaCl2 25.07 mg, H2O 106 \u03bcL, piracetam 0.079, CaCl2 0.034, H2O 0.886 at 298.15 K"}, {"property name": "amount of H2O added", "value": "83", "unit": "\u03bcL", "condition": "sample no. 5, total amount of H2O 133 \u03bcL, piracetam 65.77 mg, CaCl2 34.23 mg, H2O 133 \u03bcL, piracetam 0.057, CaCl2 0.038, H2O 0.905 at 298.15 K"}, {"property name": "amount of H2O added", "value": "58", "unit": "\u03bcL", "condition": "sample no. 6, total amount of H2O 158 \u03bcL, piracetam 56.16 mg, CaCl2 43.84 mg, H2O 158 \u03bcL, piracetam 0.041, CaCl2 0.041, H2O 0.917 at 298.15 K"}, {"property name": "amount of H2O added", "value": "75", "unit": "\u03bcL", "condition": "sample no. 7, total amount of H2O 175 \u03bcL, piracetam 46.06 mg, CaCl2 53.94 mg, H2O 175 \u03bcL, piracetam 0.031, CaCl2 0.046, H2O 0.923 at 298.15 K"}, {"property name": "amount of H2O added", "value": "98", "unit": "\u03bcL", "condition": "sample no. 8, total amount of H2O 198 \u03bcL, piracetam 35.44 mg, CaCl2 64.56 mg, H2O 198 \u03bcL, piracetam 0.021, CaCl2 0.049, H2O 0.930 at 298.15 K"}, {"property name": "amount of H2O added", "value": "98", "unit": "\u03bcL", "condition": "sample no. 9, total amount of H2O 198 \u03bcL, piracetam 24.26 mg, CaCl2 75.74 mg, H2O 198 \u03bcL, piracetam 0.014, CaCl2 0.058, H2O 0.928 at 298.15 K"}, {"property name": "amount of H2O added", "value": "85", "unit": "\u03bcL", "condition": "sample no. 10, total amount of H2O 185 \u03bcL, piracetam 12.46 mg, CaCl2 87.54 mg, H2O 185 \u03bcL, piracetam 0.008, CaCl2 0.071, H2O 0.921 at 298.15 K"}, {"property name": "amount of H2O added", "value": "49", "unit": "\u03bcL", "condition": "sample no. 11, total amount of H2O 99 \u03bcL, piracetam 0 mg, CaCl2 100 mg, H2O 99 \u03bcL, piracetam 0.000, CaCl2 0.141, H2O 0.859 at 298.15 K"}]}]], "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 3. Experimental Data for the Dissolution Points at 298.15 K\n\n| sample no. | amount of H<sub>2</sub>O added (\u03bcL) | total amount of H<sub>2</sub>O (\u03bcL) | piracetam (mg) | CaCl<sub>2</sub> (mg) | H<sub>2</sub>O (\u03bcL) | piracetam | CaCl<sub>2</sub> | H<sub>2</sub>O |\n|------------|----------------------------------|-----------------------------------|----------------|----------------------|-------------------|-----------|-----------------|----------------|\n| 1          | 48                               | 98                                | 100            | 0                    | 98                | 0.115     | 0.000           | 0.885          |\n| 2          | 39                               | 89                                | 92.02          | 7.98                 | 89                | 0.114     | 0.013           | 0.873          |\n| 3          | 34                               | 84                                | 83.67          | 16.33                | 84                | 0.109     | 0.027           | 0.864          |\n| 4          | 56                               | 106                               | 74.93          | 25.07                | 106               | 0.079     | 0.034           | 0.886          |\n| 5          | 83                               | 133                               | 65.77          | 34.23                | 133               | 0.057     | 0.038           | 0.905          |\n| 6          | 58                               | 158                               | 56.16          | 43.84                | 158               | 0.041     | 0.041           | 0.917          |\n| 7          | 75                               | 175                               | 46.06          | 53.94                | 175               | 0.031     | 0.046           | 0.923          |\n| 8          | 98                               | 198                               | 35.44          | 64.56                | 198               | 0.021     | 0.049           | 0.930          |\n| 9          | 98                               | 198                               | 24.26          | 75.74                | 198               | 0.014     | 0.058           | 0.928          |\n| 10         | 85                               | 185                               | 12.46          | 87.54                | 185               | 0.008     | 0.071           | 0.921          |\n| 11         | 49                               | 99                                | 0              | 100                  | 99                | 0.000     | 0.141           | 0.859          |\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"48\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 1, total amount of H2O 98 \u03bcL, piracetam 100 mg, CaCl2 0 mg, H2O 98 \u03bcL, piracetam 0.115, CaCl2 0.000, H2O 0.885 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"39\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 2, total amount of H2O 89 \u03bcL, piracetam 92.02 mg, CaCl2 7.98 mg, H2O 89 \u03bcL, piracetam 0.114, CaCl2 0.013, H2O 0.873 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"34\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 3, total amount of H2O 84 \u03bcL, piracetam 83.67 mg, CaCl2 16.33 mg, H2O 84 \u03bcL, piracetam 0.109, CaCl2 0.027, H2O 0.864 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"56\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 4, total amount of H2O 106 \u03bcL, piracetam 74.93 mg, CaCl2 25.07 mg, H2O 106 \u03bcL, piracetam 0.079, CaCl2 0.034, H2O 0.886 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"83\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 5, total amount of H2O 133 \u03bcL, piracetam 65.77 mg, CaCl2 34.23 mg, H2O 133 \u03bcL, piracetam 0.057, CaCl2 0.038, H2O 0.905 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"58\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 6, total amount of H2O 158 \u03bcL, piracetam 56.16 mg, CaCl2 43.84 mg, H2O 158 \u03bcL, piracetam 0.041, CaCl2 0.041, H2O 0.917 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"75\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 7, total amount of H2O 175 \u03bcL, piracetam 46.06 mg, CaCl2 53.94 mg, H2O 175 \u03bcL, piracetam 0.031, CaCl2 0.046, H2O 0.923 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"98\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 8, total amount of H2O 198 \u03bcL, piracetam 35.44 mg, CaCl2 64.56 mg, H2O 198 \u03bcL, piracetam 0.021, CaCl2 0.049, H2O 0.930 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"98\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 9, total amount of H2O 198 \u03bcL, piracetam 24.26 mg, CaCl2 75.74 mg, H2O 198 \u03bcL, piracetam 0.014, CaCl2 0.058, H2O 0.928 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"85\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 10, total amount of H2O 185 \u03bcL, piracetam 12.46 mg, CaCl2 87.54 mg, H2O 185 \u03bcL, piracetam 0.008, CaCl2 0.071, H2O 0.921 at 298.15 K\",\n            },\n            {\n                \"property name\": \"amount of H2O added\",\n                \"value\": \"49\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 11, total amount of H2O 99 \u03bcL, piracetam 0 mg, CaCl2 100 mg, H2O 99 \u03bcL, piracetam 0.000, CaCl2 0.141, H2O 0.859 at 298.15 K\",\n            }\n        ],\n    }\n]\n```"}}, {"idx": 29, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"tbl4\" position=\"float\">\n<label>4</label>\n<caption>\n<title>Initial Experimental Data for System\nof Piracetam-CaCl<sub>2</sub> in 30 g\u00b7L<sup>\u20131</sup> NaCl\nAqueous Solution at 298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"8\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"left\" colname=\"col8\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col4\" namest=\"col2\" rowsep=\"1\">initial\ncomponents</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col7\" namest=\"col5\" rowsep=\"1\">initial\ncomponents (mol\u00a0%)</oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">solvent (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">solvent</oasis:entry>\n<oasis:entry align=\"center\">solid phase at equilibrium<xref ref-type=\"table-fn\" rid=\"t4fn1\"></xref>\n</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.153</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.847</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.141</oasis:entry>\n<oasis:entry>0.016</oasis:entry>\n<oasis:entry>0.844</oasis:entry>\n<oasis:entry>Pi</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.127</oasis:entry>\n<oasis:entry>0.032</oasis:entry>\n<oasis:entry>0.841</oasis:entry>\n<oasis:entry>Pi\u00a0+\u00a0CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.114</oasis:entry>\n<oasis:entry>0.049</oasis:entry>\n<oasis:entry>0.838</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.099</oasis:entry>\n<oasis:entry>0.066</oasis:entry>\n<oasis:entry>0.834</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.085</oasis:entry>\n<oasis:entry>0.084</oasis:entry>\n<oasis:entry>0.831</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.069</oasis:entry>\n<oasis:entry>0.104</oasis:entry>\n<oasis:entry>0.827</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.053</oasis:entry>\n<oasis:entry>0.123</oasis:entry>\n<oasis:entry>0.824</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.036</oasis:entry>\n<oasis:entry>0.144</oasis:entry>\n<oasis:entry>0.820</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0.018</oasis:entry>\n<oasis:entry>0.166</oasis:entry>\n<oasis:entry>0.816</oasis:entry>\n<oasis:entry>CC</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>70</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>0.188</oasis:entry>\n<oasis:entry>0.812</oasis:entry>\n<oasis:entry>CaCl<sub>2</sub>\n</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n<table-wrap-foot>\n<fn id=\"t4fn1\">\n<label>a</label>\n<p>pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.</p>\n</fn>\n</table-wrap-foot>\n</table-wrap>", "clean_text": "Table 4. Initial Experimental Data for System of Piracetam-CaCl<sub>2</sub> in 30 g\u00b7L<sup>\u20131</sup> NaCl Aqueous Solution at 298.15 K\n\n|              | initial components | initial components (mol\u00a0%) |              |              |              |              |              | solid phase at equilibrium[^a] |\n| sample no.   | piracetam (mg)      | CaCl<sub>2</sub> (mg)        | solvent (\u03bcL) | piracetam    | CaCl<sub>2</sub> | solvent      |              |                                 |\n|--------------|---------------------|-----------------------------|--------------|--------------|-----------------|--------------|--------------|---------------------------------|\n| 1            | 100                 | 0                             | 70           | 0.153        | 0               | 0.847        | Pi           |                                 |\n| 2            | 92.02               | 7.98                          | 70           | 0.141        | 0.016           | 0.844        | Pi           |                                 |\n| 3            | 83.67               | 16.33                         | 70           | 0.127        | 0.032           | 0.841        | Pi\u00a0+\u00a0CC      |                                 |\n| 4            | 74.93               | 25.07                         | 70           | 0.114        | 0.049           | 0.838        | CC           |                                 |\n| 5            | 65.77               | 34.23                         | 70           | 0.099        | 0.066           | 0.834        | CC           |                                 |\n| 6            | 56.16               | 43.84                         | 70           | 0.085        | 0.084           | 0.831        | CC           |                                 |\n| 7            | 46.06               | 53.94                         | 70           | 0.069        | 0.104           | 0.827        | CC           |                                 |\n| 8            | 35.44               | 64.56                         | 70           | 0.053        | 0.123           | 0.824        | CC           |                                 |\n| 9            | 24.26               | 75.74                         | 70           | 0.036        | 0.144           | 0.820        | CC           |                                 |\n| 10           | 12.46               | 87.54                         | 70           | 0.018        | 0.166           | 0.816        | CC           |                                 |\n| 11           | 0                   | 100                           | 70           | 0            | 0.188           | 0.812        | CaCl<sub>2</sub> |                                 |\n\n[^a]: pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.", "data": [[{"meta": {"name": "Piracetam-CaCl2 System", "symbol": "", "chemical formula": "C6H10N2O2-CaCl2"}, "etc": [{"property name": "initial components", "sample no.": "1", "piracetam (mg)": "100", "CaCl2 (mg)": "0", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.153", "CaCl2 (mol %)": "0", "solvent (mol %)": "0.847", "solid phase at equilibrium": "Pi"}, {"property name": "initial components", "sample no.": "2", "piracetam (mg)": "92.02", "CaCl2 (mg)": "7.98", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.141", "CaCl2 (mol %)": "0.016", "solvent (mol %)": "0.844", "solid phase at equilibrium": "Pi"}, {"property name": "initial components", "sample no.": "3", "piracetam (mg)": "83.67", "CaCl2 (mg)": "16.33", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.127", "CaCl2 (mol %)": "0.032", "solvent (mol %)": "0.841", "solid phase at equilibrium": "Pi + CC"}, {"property name": "initial components", "sample no.": "4", "piracetam (mg)": "74.93", "CaCl2 (mg)": "25.07", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.114", "CaCl2 (mol %)": "0.049", "solvent (mol %)": "0.838", "solid phase at equilibrium": "CC"}, {"property name": "initial components", "sample no.": "5", "piracetam (mg)": "65.77", "CaCl2 (mg)": "34.23", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.099", "CaCl2 (mol %)": "0.066", "solvent (mol %)": "0.834", "solid phase at equilibrium": "CC"}, {"property name": "initial components", "sample no.": "6", "piracetam (mg)": "56.16", "CaCl2 (mg)": "43.84", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.085", "CaCl2 (mol %)": "0.084", "solvent (mol %)": "0.831", "solid phase at equilibrium": "CC"}, {"property name": "initial components", "sample no.": "7", "piracetam (mg)": "46.06", "CaCl2 (mg)": "53.94", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.069", "CaCl2 (mol %)": "0.104", "solvent (mol %)": "0.827", "solid phase at equilibrium": "CC"}, {"property name": "initial components", "sample no.": "8", "piracetam (mg)": "35.44", "CaCl2 (mg)": "64.56", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.053", "CaCl2 (mol %)": "0.123", "solvent (mol %)": "0.824", "solid phase at equilibrium": "CC"}, {"property name": "initial components", "sample no.": "9", "piracetam (mg)": "24.26", "CaCl2 (mg)": "75.74", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.036", "CaCl2 (mol %)": "0.144", "solvent (mol %)": "0.820", "solid phase at equilibrium": "CC"}, {"property name": "initial components", "sample no.": "10", "piracetam (mg)": "12.46", "CaCl2 (mg)": "87.54", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0.018", "CaCl2 (mol %)": "0.166", "solvent (mol %)": "0.816", "solid phase at equilibrium": "CC"}, {"property name": "initial components", "sample no.": "11", "piracetam (mg)": "0", "CaCl2 (mg)": "100", "solvent (\u03bcL)": "70", "piracetam (mol %)": "0", "CaCl2 (mol %)": "0.188", "solvent (mol %)": "0.812", "solid phase at equilibrium": "CaCl2"}]}]], "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 4. Initial Experimental Data for System of Piracetam-CaCl<sub>2</sub> in 30 g\u00b7L<sup>\u20131</sup> NaCl Aqueous Solution at 298.15 K\n\n|              | initial components | initial components (mol\u00a0%) |              |              |              |              |              | solid phase at equilibrium[^a] |\n| sample no.   | piracetam (mg)      | CaCl<sub>2</sub> (mg)        | solvent (\u03bcL) | piracetam    | CaCl<sub>2</sub> | solvent      |              |                                 |\n|--------------|---------------------|-----------------------------|--------------|--------------|-----------------|--------------|--------------|---------------------------------|\n| 1            | 100                 | 0                             | 70           | 0.153        | 0               | 0.847        | Pi           |                                 |\n| 2            | 92.02               | 7.98                          | 70           | 0.141        | 0.016           | 0.844        | Pi           |                                 |\n| 3            | 83.67               | 16.33                         | 70           | 0.127        | 0.032           | 0.841        | Pi\u00a0+\u00a0CC      |                                 |\n| 4            | 74.93               | 25.07                         | 70           | 0.114        | 0.049           | 0.838        | CC           |                                 |\n| 5            | 65.77               | 34.23                         | 70           | 0.099        | 0.066           | 0.834        | CC           |                                 |\n| 6            | 56.16               | 43.84                         | 70           | 0.085        | 0.084           | 0.831        | CC           |                                 |\n| 7            | 46.06               | 53.94                         | 70           | 0.069        | 0.104           | 0.827        | CC           |                                 |\n| 8            | 35.44               | 64.56                         | 70           | 0.053        | 0.123           | 0.824        | CC           |                                 |\n| 9            | 24.26               | 75.74                         | 70           | 0.036        | 0.144           | 0.820        | CC           |                                 |\n| 10           | 12.46               | 87.54                         | 70           | 0.018        | 0.166           | 0.816        | CC           |                                 |\n| 11           | 0                   | 100                           | 70           | 0            | 0.188           | 0.812        | CaCl<sub>2</sub> |                                 |\n\n[^a]: pi: piracetam; CC: Piracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"Piracetam-CaCl2 System\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"C6H10N2O2-CaCl2\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"1\",\n                \"piracetam (mg)\": \"100\",\n                \"CaCl2 (mg)\": \"0\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.153\",\n                \"CaCl2 (mol %)\": \"0\",\n                \"solvent (mol %)\": \"0.847\",\n                \"solid phase at equilibrium\": \"Pi\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"2\",\n                \"piracetam (mg)\": \"92.02\",\n                \"CaCl2 (mg)\": \"7.98\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.141\",\n                \"CaCl2 (mol %)\": \"0.016\",\n                \"solvent (mol %)\": \"0.844\",\n                \"solid phase at equilibrium\": \"Pi\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"3\",\n                \"piracetam (mg)\": \"83.67\",\n                \"CaCl2 (mg)\": \"16.33\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.127\",\n                \"CaCl2 (mol %)\": \"0.032\",\n                \"solvent (mol %)\": \"0.841\",\n                \"solid phase at equilibrium\": \"Pi + CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"4\",\n                \"piracetam (mg)\": \"74.93\",\n                \"CaCl2 (mg)\": \"25.07\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.114\",\n                \"CaCl2 (mol %)\": \"0.049\",\n                \"solvent (mol %)\": \"0.838\",\n                \"solid phase at equilibrium\": \"CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"5\",\n                \"piracetam (mg)\": \"65.77\",\n                \"CaCl2 (mg)\": \"34.23\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.099\",\n                \"CaCl2 (mol %)\": \"0.066\",\n                \"solvent (mol %)\": \"0.834\",\n                \"solid phase at equilibrium\": \"CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"6\",\n                \"piracetam (mg)\": \"56.16\",\n                \"CaCl2 (mg)\": \"43.84\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.085\",\n                \"CaCl2 (mol %)\": \"0.084\",\n                \"solvent (mol %)\": \"0.831\",\n                \"solid phase at equilibrium\": \"CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"7\",\n                \"piracetam (mg)\": \"46.06\",\n                \"CaCl2 (mg)\": \"53.94\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.069\",\n                \"CaCl2 (mol %)\": \"0.104\",\n                \"solvent (mol %)\": \"0.827\",\n                \"solid phase at equilibrium\": \"CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"8\",\n                \"piracetam (mg)\": \"35.44\",\n                \"CaCl2 (mg)\": \"64.56\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.053\",\n                \"CaCl2 (mol %)\": \"0.123\",\n                \"solvent (mol %)\": \"0.824\",\n                \"solid phase at equilibrium\": \"CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"9\",\n                \"piracetam (mg)\": \"24.26\",\n                \"CaCl2 (mg)\": \"75.74\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.036\",\n                \"CaCl2 (mol %)\": \"0.144\",\n                \"solvent (mol %)\": \"0.820\",\n                \"solid phase at equilibrium\": \"CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"10\",\n                \"piracetam (mg)\": \"12.46\",\n                \"CaCl2 (mg)\": \"87.54\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0.018\",\n                \"CaCl2 (mol %)\": \"0.166\",\n                \"solvent (mol %)\": \"0.816\",\n                \"solid phase at equilibrium\": \"CC\"\n            },\n            {\n                \"property name\": \"initial components\",\n                \"sample no.\": \"11\",\n                \"piracetam (mg)\": \"0\",\n                \"CaCl2 (mg)\": \"100\",\n                \"solvent (\u03bcL)\": \"70\",\n                \"piracetam (mol %)\": \"0\",\n                \"CaCl2 (mol %)\": \"0.188\",\n                \"solvent (mol %)\": \"0.812\",\n                \"solid phase at equilibrium\": \"CaCl2\"\n            }\n        ]\n    }\n]\n```"}}, {"idx": 31, "type": "table", "classification": ["Property"], "content": "<table-wrap id=\"tbl5\" position=\"float\">\n<label>5</label>\n<caption>\n<title>Experimental Data for Dissolution\nPoints in 30 g\u00b7L<sup>\u20131</sup> NaCl Aqueous Solution at\n298.15 K</title>\n</caption>\n<oasis:table colsep=\"0\" rowsep=\"0\">\n<oasis:tgroup cols=\"9\">\n<oasis:colspec align=\"left\" colname=\"col1\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col2\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col3\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col4\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col5\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col6\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col7\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col8\"></oasis:colspec>\n<oasis:colspec align=\"char\" char=\".\" colname=\"col9\"></oasis:colspec>\n<oasis:thead>\n<oasis:row>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\"></oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col6\" namest=\"col4\" rowsep=\"1\">components\nat dissolution point</oasis:entry>\n<oasis:entry align=\"center\" nameend=\"col9\" namest=\"col7\" rowsep=\"1\">components\nat dissolution point (mol\u00a0%)</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry align=\"center\">sample no.</oasis:entry>\n<oasis:entry align=\"center\">amount of solvent added (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">total amount of solvent (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam (mg)</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub> (mg)</oasis:entry>\n<oasis:entry align=\"center\">solvent (\u03bcL)</oasis:entry>\n<oasis:entry align=\"center\">piracetam</oasis:entry>\n<oasis:entry align=\"center\">CaCl<sub>2</sub>\n</oasis:entry>\n<oasis:entry align=\"center\">solvent</oasis:entry>\n</oasis:row>\n</oasis:thead>\n<oasis:tbody>\n<oasis:row>\n<oasis:entry>1</oasis:entry>\n<oasis:entry>61</oasis:entry>\n<oasis:entry>131</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>131</oasis:entry>\n<oasis:entry>0.088</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.912</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>2</oasis:entry>\n<oasis:entry>55</oasis:entry>\n<oasis:entry>125</oasis:entry>\n<oasis:entry>92.02</oasis:entry>\n<oasis:entry>7.98</oasis:entry>\n<oasis:entry>125</oasis:entry>\n<oasis:entry>0.085</oasis:entry>\n<oasis:entry>0.009</oasis:entry>\n<oasis:entry>0.906</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>3</oasis:entry>\n<oasis:entry>58</oasis:entry>\n<oasis:entry>128</oasis:entry>\n<oasis:entry>83.67</oasis:entry>\n<oasis:entry>16.33</oasis:entry>\n<oasis:entry>128</oasis:entry>\n<oasis:entry>0.075</oasis:entry>\n<oasis:entry>0.019</oasis:entry>\n<oasis:entry>0.906</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>4</oasis:entry>\n<oasis:entry>94</oasis:entry>\n<oasis:entry>164</oasis:entry>\n<oasis:entry>74.93</oasis:entry>\n<oasis:entry>25.07</oasis:entry>\n<oasis:entry>164</oasis:entry>\n<oasis:entry>0.054</oasis:entry>\n<oasis:entry>0.023</oasis:entry>\n<oasis:entry>0.923</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>5</oasis:entry>\n<oasis:entry>127</oasis:entry>\n<oasis:entry>197</oasis:entry>\n<oasis:entry>65.77</oasis:entry>\n<oasis:entry>34.23</oasis:entry>\n<oasis:entry>197</oasis:entry>\n<oasis:entry>0.040</oasis:entry>\n<oasis:entry>0.026</oasis:entry>\n<oasis:entry>0.934</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>6</oasis:entry>\n<oasis:entry>152</oasis:entry>\n<oasis:entry>222</oasis:entry>\n<oasis:entry>56.16</oasis:entry>\n<oasis:entry>43.84</oasis:entry>\n<oasis:entry>222</oasis:entry>\n<oasis:entry>0.030</oasis:entry>\n<oasis:entry>0.030</oasis:entry>\n<oasis:entry>0.940</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>7</oasis:entry>\n<oasis:entry>173</oasis:entry>\n<oasis:entry>243</oasis:entry>\n<oasis:entry>46.06</oasis:entry>\n<oasis:entry>53.94</oasis:entry>\n<oasis:entry>243</oasis:entry>\n<oasis:entry>0.023</oasis:entry>\n<oasis:entry>0.034</oasis:entry>\n<oasis:entry>0.943</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>8</oasis:entry>\n<oasis:entry>192</oasis:entry>\n<oasis:entry>262</oasis:entry>\n<oasis:entry>35.44</oasis:entry>\n<oasis:entry>64.56</oasis:entry>\n<oasis:entry>262</oasis:entry>\n<oasis:entry>0.016</oasis:entry>\n<oasis:entry>0.038</oasis:entry>\n<oasis:entry>0.946</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>9</oasis:entry>\n<oasis:entry>203</oasis:entry>\n<oasis:entry>273</oasis:entry>\n<oasis:entry>24.26</oasis:entry>\n<oasis:entry>75.74</oasis:entry>\n<oasis:entry>273</oasis:entry>\n<oasis:entry>0.011</oasis:entry>\n<oasis:entry>0.043</oasis:entry>\n<oasis:entry>0.947</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>10</oasis:entry>\n<oasis:entry>193</oasis:entry>\n<oasis:entry>263</oasis:entry>\n<oasis:entry>12.46</oasis:entry>\n<oasis:entry>87.54</oasis:entry>\n<oasis:entry>263</oasis:entry>\n<oasis:entry>0.006</oasis:entry>\n<oasis:entry>0.051</oasis:entry>\n<oasis:entry>0.943</oasis:entry>\n</oasis:row>\n<oasis:row>\n<oasis:entry>11</oasis:entry>\n<oasis:entry>163</oasis:entry>\n<oasis:entry>233</oasis:entry>\n<oasis:entry>0</oasis:entry>\n<oasis:entry>100</oasis:entry>\n<oasis:entry>233</oasis:entry>\n<oasis:entry>0.000</oasis:entry>\n<oasis:entry>0.065</oasis:entry>\n<oasis:entry>0.935</oasis:entry>\n</oasis:row>\n</oasis:tbody>\n</oasis:tgroup>\n</oasis:table>\n</table-wrap>", "clean_text": "Table 5. Experimental Data for Dissolution Points in 30 g\u00b7L\u20131 NaCl Aqueous Solution at 298.15 K\n\n| sample no. | amount of solvent added (\u03bcL) | total amount of solvent (\u03bcL) | components at dissolution point | components at dissolution point (mol %) | components at dissolution point | components at dissolution point | components at dissolution point |\n|------------|-------------------------------|-------------------------------|----------------------------------|----------------------------------------|----------------------------------|----------------------------------|----------------------------------|\n|            |                               |                               | piracetam (mg)                   | CaCl2 (mg)                              | solvent (\u03bcL)                     | piracetam                        | CaCl2                            | solvent                          |\n| 1          | 61                            | 131                           | 100                              | 0                                      | 131                              | 0.088                            | 0.000                            | 0.912                            |\n| 2          | 55                            | 125                           | 92.02                            | 7.98                                   | 125                              | 0.085                            | 0.009                            | 0.906                            |\n| 3          | 58                            | 128                           | 83.67                            | 16.33                                  | 128                              | 0.075                            | 0.019                            | 0.906                            |\n| 4          | 94                            | 164                           | 74.93                            | 25.07                                  | 164                              | 0.054                            | 0.023                            | 0.923                            |\n| 5          | 127                           | 197                           | 65.77                            | 34.23                                  | 197                              | 0.040                            | 0.026                            | 0.934                            |\n| 6          | 152                           | 222                           | 56.16                            | 43.84                                  | 222                              | 0.030                            | 0.030                            | 0.940                            |\n| 7          | 173                           | 243                           | 46.06                            | 53.94                                  | 243                              | 0.023                            | 0.034                            | 0.943                            |\n| 8          | 192                           | 262                           | 35.44                            | 64.56                                  | 262                              | 0.016                            | 0.038                            | 0.946                            |\n| 9          | 203                           | 273                           | 24.26                            | 75.74                                  | 273                              | 0.011                            | 0.043                            | 0.947                            |\n| 10         | 193                           | 263                           | 12.46                            | 87.54                                  | 263                              | 0.006                            | 0.051                            | 0.943                            |\n| 11         | 163                           | 233                           | 0                                | 100                                    | 233                              | 0.000                            | 0.065                            | 0.935                            |", "data": [[{"meta": {"name": "", "symbol": "", "chemical formula": ""}, "etc": [{"property name": "amount of solvent added", "value": "61", "unit": "\u03bcL", "condition": "sample no. 1"}, {"property name": "total amount of solvent", "value": "131", "unit": "\u03bcL", "condition": "sample no. 1"}, {"property name": "components at dissolution point", "value": "100", "unit": "mg", "condition": "sample no. 1, piracetam"}, {"property name": "components at dissolution point", "value": "0", "unit": "mg", "condition": "sample no. 1, CaCl2"}, {"property name": "components at dissolution point", "value": "131", "unit": "\u03bcL", "condition": "sample no. 1, solvent"}, {"property name": "components at dissolution point", "value": "0.088", "unit": "mol %", "condition": "sample no. 1, piracetam"}, {"property name": "components at dissolution point", "value": "0.000", "unit": "mol %", "condition": "sample no. 1, CaCl2"}, {"property name": "components at dissolution point", "value": "0.912", "unit": "mol %", "condition": "sample no. 1, solvent"}, {"property name": "amount of solvent added", "value": "55", "unit": "\u03bcL", "condition": "sample no. 2"}, {"property name": "total amount of solvent", "value": "125", "unit": "\u03bcL", "condition": "sample no. 2"}, {"property name": "components at dissolution point", "value": "92.02", "unit": "mg", "condition": "sample no. 2, piracetam"}, {"property name": "components at dissolution point", "value": "7.98", "unit": "mg", "condition": "sample no. 2, CaCl2"}, {"property name": "components at dissolution point", "value": "125", "unit": "\u03bcL", "condition": "sample no. 2, solvent"}, {"property name": "components at dissolution point", "value": "0.085", "unit": "mol %", "condition": "sample no. 2, piracetam"}, {"property name": "components at dissolution point", "value": "0.009", "unit": "mol %", "condition": "sample no. 2, CaCl2"}, {"property name": "components at dissolution point", "value": "0.906", "unit": "mol %", "condition": "sample no. 2, solvent"}, {"property name": "amount of solvent added", "value": "58", "unit": "\u03bcL", "condition": "sample no. 3"}, {"property name": "total amount of solvent", "value": "128", "unit": "\u03bcL", "condition": "sample no. 3"}, {"property name": "components at dissolution point", "value": "83.67", "unit": "mg", "condition": "sample no. 3, piracetam"}, {"property name": "components at dissolution point", "value": "16.33", "unit": "mg", "condition": "sample no. 3, CaCl2"}, {"property name": "components at dissolution point", "value": "128", "unit": "\u03bcL", "condition": "sample no. 3, solvent"}, {"property name": "components at dissolution point", "value": "0.075", "unit": "mol %", "condition": "sample no. 3, piracetam"}, {"property name": "components at dissolution point", "value": "0.019", "unit": "mol %", "condition": "sample no. 3, CaCl2"}, {"property name": "components at dissolution point", "value": "0.906", "unit": "mol %", "condition": "sample no. 3, solvent"}, {"property name": "amount of solvent added", "value": "94", "unit": "\u03bcL", "condition": "sample no. 4"}, {"property name": "total amount of solvent", "value": "164", "unit": "\u03bcL", "condition": "sample no. 4"}, {"property name": "components at dissolution point", "value": "74.93", "unit": "mg", "condition": "sample no. 4, piracetam"}, {"property name": "components at dissolution point", "value": "25.07", "unit": "mg", "condition": "sample no. 4, CaCl2"}, {"property name": "components at dissolution point", "value": "164", "unit": "\u03bcL", "condition": "sample no. 4, solvent"}, {"property name": "components at dissolution point", "value": "0.054", "unit": "mol %", "condition": "sample no. 4, piracetam"}, {"property name": "components at dissolution point", "value": "0.023", "unit": "mol %", "condition": "sample no. 4, CaCl2"}, {"property name": "components at dissolution point", "value": "0.923", "unit": "mol %", "condition": "sample no. 4, solvent"}, {"property name": "amount of solvent added", "value": "127", "unit": "\u03bcL", "condition": "sample no. 5"}, {"property name": "total amount of solvent", "value": "197", "unit": "\u03bcL", "condition": "sample no. 5"}, {"property name": "components at dissolution point", "value": "65.77", "unit": "mg", "condition": "sample no. 5, piracetam"}, {"property name": "components at dissolution point", "value": "34.23", "unit": "mg", "condition": "sample no. 5, CaCl2"}, {"property name": "components at dissolution point", "value": "197", "unit": "\u03bcL", "condition": "sample no. 5, solvent"}, {"property name": "components at dissolution point", "value": "0.040", "unit": "mol %", "condition": "sample no. 5, piracetam"}, {"property name": "components at dissolution point", "value": "0.026", "unit": "mol %", "condition": "sample no. 5, CaCl2"}, {"property name": "components at dissolution point", "value": "0.934", "unit": "mol %", "condition": "sample no. 5, solvent"}, {"property name": "amount of solvent added", "value": "152", "unit": "\u03bcL", "condition": "sample no. 6"}, {"property name": "total amount of solvent", "value": "222", "unit": "\u03bcL", "condition": "sample no. 6"}, {"property name": "components at dissolution point", "value": "56.16", "unit": "mg", "condition": "sample no. 6, piracetam"}, {"property name": "components at dissolution point", "value": "43.84", "unit": "mg", "condition": "sample no. 6, CaCl2"}, {"property name": "components at dissolution point", "value": "222", "unit": "\u03bcL", "condition": "sample no. 6, solvent"}, {"property name": "components at dissolution point", "value": "0.030", "unit": "mol %", "condition": "sample no. 6, piracetam"}, {"property name": "components at dissolution point", "value": "0.030", "unit": "mol %", "condition": "sample no. 6, CaCl2"}, {"property name": "components at dissolution point", "value": "0.940", "unit": "mol %", "condition": "sample no. 6, solvent"}, {"property name": "amount of solvent added", "value": "173", "unit": "\u03bcL", "condition": "sample no. 7"}, {"property name": "total amount of solvent", "value": "243", "unit": "\u03bcL", "condition": "sample no. 7"}, {"property name": "components at dissolution point", "value": "46.06", "unit": "mg", "condition": "sample no. 7, piracetam"}, {"property name": "components at dissolution point", "value": "53.94", "unit": "mg", "condition": "sample no. 7, CaCl2"}, {"property name": "components at dissolution point", "value": "243", "unit": "\u03bcL", "condition": "sample no. 7, solvent"}, {"property name": "components at dissolution point", "value": "0.023", "unit": "mol %", "condition": "sample no. 7, piracetam"}, {"property name": "components at dissolution point", "value": "0.034", "unit": "mol %", "condition": "sample no. 7, CaCl2"}, {"property name": "components at dissolution point", "value": "0.943", "unit": "mol %", "condition": "sample no. 7, solvent"}, {"property name": "amount of solvent added", "value": "192", "unit": "\u03bcL", "condition": "sample no. 8"}, {"property name": "total amount of solvent", "value": "262", "unit": "\u03bcL", "condition": "sample no. 8"}, {"property name": "components at dissolution point", "value": "35.44", "unit": "mg", "condition": "sample no. 8, piracetam"}, {"property name": "components at dissolution point", "value": "64.56", "unit": "mg", "condition": "sample no. 8, CaCl2"}, {"property name": "components at dissolution point", "value": "262", "unit": "\u03bcL", "condition": "sample no. 8, solvent"}, {"property name": "components at dissolution point", "value": "0.016", "unit": "mol %", "condition": "sample no. 8, piracetam"}, {"property name": "components at dissolution point", "value": "0.038", "unit": "mol %", "condition": "sample no. 8, CaCl2"}, {"property name": "components at dissolution point", "value": "0.946", "unit": "mol %", "condition": "sample no. 8, solvent"}, {"property name": "amount of solvent added", "value": "203", "unit": "\u03bcL", "condition": "sample no. 9"}, {"property name": "total amount of solvent", "value": "273", "unit": "\u03bcL", "condition": "sample no. 9"}, {"property name": "components at dissolution point", "value": "24.26", "unit": "mg", "condition": "sample no. 9, piracetam"}, {"property name": "components at dissolution point", "value": "75.74", "unit": "mg", "condition": "sample no. 9, CaCl2"}, {"property name": "components at dissolution point", "value": "273", "unit": "\u03bcL", "condition": "sample no. 9, solvent"}, {"property name": "components at dissolution point", "value": "0.011", "unit": "mol %", "condition": "sample no. 9, piracetam"}, {"property name": "components at dissolution point", "value": "0.043", "unit": "mol %", "condition": "sample no. 9, CaCl2"}, {"property name": "components at dissolution point", "value": "0.947", "unit": "mol %", "condition": "sample no. 9, solvent"}, {"property name": "amount of solvent added", "value": "193", "unit": "\u03bcL", "condition": "sample no. 10"}, {"property name": "total amount of solvent", "value": "263", "unit": "\u03bcL", "condition": "sample no. 10"}, {"property name": "components at dissolution point", "value": "12.46", "unit": "mg", "condition": "sample no. 10, piracetam"}, {"property name": "components at dissolution point", "value": "87.54", "unit": "mg", "condition": "sample no. 10, CaCl2"}, {"property name": "components at dissolution point", "value": "263", "unit": "\u03bcL", "condition": "sample no. 10, solvent"}, {"property name": "components at dissolution point", "value": "0.006", "unit": "mol %", "condition": "sample no. 10, piracetam"}, {"property name": "components at dissolution point", "value": "0.051", "unit": "mol %", "condition": "sample no. 10, CaCl2"}, {"property name": "components at dissolution point", "value": "0.943", "unit": "mol %", "condition": "sample no. 10, solvent"}, {"property name": "amount of solvent added", "value": "163", "unit": "\u03bcL", "condition": "sample no. 11"}, {"property name": "total amount of solvent", "value": "233", "unit": "\u03bcL", "condition": "sample no. 11"}, {"property name": "components at dissolution point", "value": "0", "unit": "mg", "condition": "sample no. 11, piracetam"}, {"property name": "components at dissolution point", "value": "100", "unit": "mg", "condition": "sample no. 11, CaCl2"}, {"property name": "components at dissolution point", "value": "233", "unit": "\u03bcL", "condition": "sample no. 11, solvent"}, {"property name": "components at dissolution point", "value": "0.000", "unit": "mol %", "condition": "sample no. 11, piracetam"}, {"property name": "components at dissolution point", "value": "0.065", "unit": "mol %", "condition": "sample no. 11, CaCl2"}, {"property name": "components at dissolution point", "value": "0.935", "unit": "mol %", "condition": "sample no. 11, solvent"}]}]], "include_properties": ["etc"], "intermediate_step": {"table-convert2MD": "[gpt.ft]Table 5. Experimental Data for Dissolution Points in 30 g\u00b7L\u20131 NaCl Aqueous Solution at 298.15 K\n\n| sample no. | amount of solvent added (\u03bcL) | total amount of solvent (\u03bcL) | components at dissolution point | components at dissolution point (mol %) | components at dissolution point | components at dissolution point | components at dissolution point |\n|------------|-------------------------------|-------------------------------|----------------------------------|----------------------------------------|----------------------------------|----------------------------------|----------------------------------|\n|            |                               |                               | piracetam (mg)                   | CaCl2 (mg)                              | solvent (\u03bcL)                     | piracetam                        | CaCl2                            | solvent                          |\n| 1          | 61                            | 131                           | 100                              | 0                                      | 131                              | 0.088                            | 0.000                            | 0.912                            |\n| 2          | 55                            | 125                           | 92.02                            | 7.98                                   | 125                              | 0.085                            | 0.009                            | 0.906                            |\n| 3          | 58                            | 128                           | 83.67                            | 16.33                                  | 128                              | 0.075                            | 0.019                            | 0.906                            |\n| 4          | 94                            | 164                           | 74.93                            | 25.07                                  | 164                              | 0.054                            | 0.023                            | 0.923                            |\n| 5          | 127                           | 197                           | 65.77                            | 34.23                                  | 197                              | 0.040                            | 0.026                            | 0.934                            |\n| 6          | 152                           | 222                           | 56.16                            | 43.84                                  | 222                              | 0.030                            | 0.030                            | 0.940                            |\n| 7          | 173                           | 243                           | 46.06                            | 53.94                                  | 243                              | 0.023                            | 0.034                            | 0.943                            |\n| 8          | 192                           | 262                           | 35.44                            | 64.56                                  | 262                              | 0.016                            | 0.038                            | 0.946                            |\n| 9          | 203                           | 273                           | 24.26                            | 75.74                                  | 273                              | 0.011                            | 0.043                            | 0.947                            |\n| 10         | 193                           | 263                           | 12.46                            | 87.54                                  | 263                              | 0.006                            | 0.051                            | 0.943                            |\n| 11         | 163                           | 233                           | 0                                | 100                                    | 233                              | 0.000                            | 0.065                            | 0.935                            |\n<END>", "table-categorize": "Property", "table-property-type": "['etc']", "table-property-extract": "```JSON\n[\n    {\n        \"meta\": {\n            \"name\": \"\",\n            \"symbol\": \"\",\n            \"chemical formula\": \"\",\n        },\n        \"etc\": [\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"61\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 1\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"131\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 1\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"100\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 1, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 1, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"131\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 1, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.088\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 1, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.000\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 1, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.912\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 1, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"55\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 2\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"125\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"92.02\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 2, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"7.98\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 2, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"125\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 2, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.085\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 2, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.009\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 2, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.906\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 2, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"58\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 3\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"128\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 3\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"83.67\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 3, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"16.33\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 3, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"128\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 3, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.075\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 3, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.019\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 3, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.906\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 3, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"94\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 4\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"164\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 4\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"74.93\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 4, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"25.07\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 4, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"164\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 4, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.054\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 4, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.023\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 4, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.923\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 4, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"127\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 5\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"197\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 5\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"65.77\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 5, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"34.23\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 5, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"197\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 5, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.040\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 5, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.026\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 5, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.934\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 5, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"152\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 6\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"222\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 6\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"56.16\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 6, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"43.84\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 6, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"222\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 6, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.030\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 6, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.030\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 6, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.940\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 6, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"173\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 7\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"243\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 7\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"46.06\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 7, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"53.94\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 7, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"243\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 7, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.023\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 7, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.034\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 7, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.943\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 7, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"192\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 8\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"262\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 8\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"35.44\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 8, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"64.56\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 8, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"262\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 8, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.016\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 8, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.038\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 8, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.946\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 8, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"203\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 9\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"273\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 9\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"24.26\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 9, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"75.74\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 9, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"273\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 9, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.011\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 9, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.043\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 9, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.947\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 9, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"193\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 10\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"263\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 10\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"12.46\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 10, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"87.54\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 10, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"263\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 10, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.006\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 10, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.051\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 10, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.943\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 10, solvent\",\n            },\n            {\n                \"property name\": \"amount of solvent added\",\n                \"value\": \"163\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 11\",\n            },\n            {\n                \"property name\": \"total amount of solvent\",\n                \"value\": \"233\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 11\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 11, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"100\",\n                \"unit\": \"mg\",\n                \"condition\": \"sample no. 11, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"233\",\n                \"unit\": \"\u03bcL\",\n                \"condition\": \"sample no. 11, solvent\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.000\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 11, piracetam\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.065\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 11, CaCl2\",\n            },\n            {\n                \"property name\": \"components at dissolution point\",\n                \"value\": \"0.935\",\n                \"unit\": \"mol %\",\n                \"condition\": \"sample no. 11, solvent\",\n            }\n        ],\n    }\n]\n```"}}, {"idx": 9, "type": "figure", "classification": null, "content": "<fig fig-type=\"scheme\" id=\"sch1\" position=\"float\">\n<label>1</label>\n<caption>\n<title>Typical\nProcess for Determining the Ternary Phase Diagram of an Ionic\nCocrystal</title>\n</caption>\n<graphic id=\"gr1\" position=\"float\" xlink:href=\"cg-2018-00352c_0006.tif\"></graphic>\n</fig>", "clean_text": " 1  Typical Process for Determining the Ternary Phase Diagram of an Ionic Cocrystal   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 15, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig1\" position=\"float\">\n<label>1</label>\n<caption>\n<p>Molecular\nstructure of piracetam.</p>\n</caption>\n<graphic id=\"gr2\" position=\"float\" xlink:href=\"cg-2018-00352c_0001.tif\"></graphic>\n</fig>", "clean_text": " 1  Molecular structure of piracetam.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 17, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig2\" position=\"float\">\n<label>2</label>\n<caption>\n<p>XRPD overlay of LAG of piracetam with CaCl<sub>2</sub> using 10\n\u03bcL of methanol (red) with the simulated XRPD of the cocrystal\n(blue).</p>\n</caption>\n<graphic id=\"gr3\" position=\"float\" xlink:href=\"cg-2018-00352c_0002.tif\"></graphic>\n</fig>", "clean_text": " 2  XRPD overlay of LAG of piracetam with CaCl2 using 10 \u03bcL of methanol (red) with the simulated XRPD of the cocrystal (blue).   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 19, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig3\" position=\"float\">\n<label>3</label>\n<caption>\n<p>Left: Coordination\naround the Ca<sup>2+</sup> cation in crystalline\npiracetam<sub>2</sub>\u00b7CaCl<sub>2</sub>\u00b72H<sub>2</sub>O.\nRight: A 2D-layer of Ca<sup>2+</sup> ions and coordinated water and\npiracetam molecules extending in the crystalline structure.</p>\n</caption>\n<graphic id=\"gr4\" position=\"float\" xlink:href=\"cg-2018-00352c_0003.tif\"></graphic>\n</fig>", "clean_text": " 3  Left: Coordination around the Ca2+ cation in crystalline piracetam2\u22c5CaCl2\u22c52H2O. Right: A 2D-layer of Ca2+ ions and coordinated water and piracetam molecules extending in the crystalline structure.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 25, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig4\" position=\"float\">\n<label>4</label>\n<caption>\n<p>TPD of water-piracetam-CaCl<sub>2</sub> at 298.15 K (mol %). The\ngreen zone highlights the zone where the cocrystal is the only stable\nphase in suspension. a: the full image of ternary phase diagram. b:\nenlargement of the upper part.</p>\n</caption>\n<graphic id=\"gr5\" position=\"float\" xlink:href=\"cg-2018-00352c_0004.tif\"></graphic>\n</fig>", "clean_text": " 4  TPD of water-piracetam-CaCl2 at 298.15 K (mol %). The green zone highlights the zone where the cocrystal is the only stable phase in suspension. a: the full image of ternary phase diagram. b: enlargement of the upper part.   ", "data": null, "include_properties": null, "intermediate_step": {}}, {"idx": 32, "type": "figure", "classification": null, "content": "<fig fig-type=\"figure\" id=\"fig5\" position=\"float\">\n<label>5</label>\n<caption>\n<p>TPD zoom picture of piracetam-CaCl<sub>2</sub> in H<sub>2</sub>O and NaCl aqueous solution at 298.15 K (mol %). The green one is\nin H<sub>2</sub>O, and the red one is in NaCl aqueous solution.</p>\n</caption>\n<graphic id=\"gr6\" position=\"float\" xlink:href=\"cg-2018-00352c_0005.tif\"></graphic>\n</fig>", "clean_text": " 5  TPD zoom picture of piracetam-CaCl2 in H2O and NaCl aqueous solution at 298.15 K (mol %). The green one is in H2O, and the red one is in NaCl aqueous solution.   ", "data": null, "include_properties": null, "intermediate_step": {}}], "metadata": {"doi": "10.1021/acs.cgd.8b00352", "title": "\nCrystallizing Ionic Cocrystals: Structural Characteristics,\nThermal Behavior, and Crystallization Development of a Piracetam-CaCl2 Cocrystallization Process\n", "journal": "American Chemical\nSociety", "date": "2018.04", "author_list": ["Song\nLixing", "Robeyns\nKoen", "Leyssens\nTom"]}}